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inTroducTion
Extrahepatic portal vein thrombosis (EPVT) is the most common cause of portal hy-
pertension in non- cirrhotic patients. EPVT has been defined as an obstruction of the 
extrahepatic portal vein with or without involvement of the intrahepatic portal veins[1]. 
Although the portal vein accounts for two third of the total hepatic blood flow, interrup-
tion of the portal vein has few clinical consequences. This could be explained by two find-
ings. First a compensatory mechanism so called arterial ’buffer’ response, which consists 
of immediate vasodilatation of the hepatic arterial bed in response to a decreased portal 
vein blood flow. This mechanism has been well demonstrated experimentally, but also 
in patients following portal vein clamping at hepatic surgery[2]. The second compensa-
tory mechanism is a rapid development of collateral veins bypassing the thrombosed 
portion of the portal vein. As a result of the arterial buffer response and development of 
collaterals, total hepatic blood flow is minimally reduced[3]. Portal pressure, however is 
increased. This increase in portal pressure can be viewed as a compensatory mechanism 
allowing portal vein perfusion to be maintained through the collateral veins. So, portal 
perfusion is maintained at the expense of portal hypertension.
The etiology of EPVT is diverse and can be divided into local risk factors such as cir-
rhosis, hepatobiliary malignancies and pancreatitis, and systemic risk factors such as 
inherited and acquired prothrombotic disorders. In at least one third of the patients a 
combination of thrombotic risk factors is demonstrated[4]. If EPVT is suspected, diag-
nosis can be rapidly established by use of noninvasive imaging, which generally reveals 
Figure 1. Anatomy of the portal vein
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the presence of solid material within the venous lumen. Ultrasonography is the imaging 
modality most frequently used.
From a clinical point of view, EPVT consists of two different entities, recent and chronic 
EPVT. They share similar causes, but differ in clinical presentation and management. A 
recent thrombosis is characterized by the sudden formation of a thrombus in the portal 
vein and usually presents with abdominal pain. When extensive thrombosis involves the 
mesenteric venous arches, intestinal ischemia and later infarction can occur[5]. Chronic 
EPVT, usually becomes manifest as a complication of the existing portal hypertension. 
The goal of treatment depends on the onset of the thrombosis. In patients with recent 
EPVT treatment is aimed to restore flow patency and prevent recurrence or extension of 
the thrombosis. In chronic EPVT patients treatment is mainly aimed to manage portal 
hypertension related complications. Variceal bleeding is the most common complica-
tion of portal hypertension. Endoscopic therapy have been found to be effective in the 
control and prevention of variceal bleeding. If endoscopic therapy fails a transjugular 
intrahepatic portosystemic shunt (TIPS), if technical applicable, can be considered. 
Another alternative that can be considered is a surgical shunt. Main problems with this 
treatment are peroperative bleeding and thrombosis of the shunt.
In the last decade new advantages and insights have been made, especially in identi-
fying prothrombotic disorders as underlying cause of EPVT [4, 6-8]. These findings have 
led to a more prominent role of anticoagulation therapy in EPVT patients [9]. However 
data on the risk and benefit of anticoagulation therapy are scarce, due to lack of large 
cohort studies. This lack of data is also seen with regard to portal hypertension related 
complications. In contrast to cirrhotic patients less is known in non cirrhotic patients 
with portal hypertension related complications.
Aims
In this thesis we aim to study the prevalence, clinical outcome and management of pa-
tients with non- cirrhotic non- malignant EPVT. In particular we studied the risk- benefit 
ratio of anticoagulation and endoscopic therapy as treatment option for complications 
related to portal hypertension in EPVT.
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ouTline oF The Thesis
chapter 1. Introduction and aims
chapter 2. This chapter gives a general overview of patients with non- cirrhotic non- 
malignant EPVT. Etiology, clinical features depending on the onset of the thrombosis 
and the corresponding treatment modalities are discussed. In patients with chronic 
EPVT clinical features are portal hypertension related.
chapter 3. The most common complication of portal hypertension in EPVT patients is 
variceal bleeding. Gastrointestinal bleeding caused by portal hypertension in patients 
with EPVT has been reported to cause death in 1.0 to 20% of the patients [9-11]. Endo-
scopic treatment is the first line intervention in patients with bleeding esophagogastric 
varices. In this chapter we describe the long-term clinical outcome and efficacy of 
endoscopic treatment in patients with esophagogastric variceal bleeding secondary to 
non cirrhotic EPVT.
chapter 4. Another phenomenon of portal hypertension is ascites. In contrast to pa-
tients with cirrhosis, where ascites is a poor prognostic feature, little is known of ascites 
in non- cirrhotic non- malignant patients with EPVT. In this chapter we assessed all pa-
tients with ascites at the time EPVT was diagnosed and observed the frequency, natural 
history and prognostic implication of ascites in these patients.
chapter 5. The role of anticoagulation therapy in patients with EPVT is ambiguous. The 
evidence is rather low due to lack of large trials. In this chapter we studied a cohort of 
patients with and without anticoagulation therapy and assessed the effect of antico-
agulation therapy on risk of gastrointestinal bleeding and recurrent thrombotic events 
in patient with EVPT.
chapter 6. Another treatment modality of recent EPVT is thrombolysis. In the last 
decade we have done transcatheter local thrombolytic therapy in patients with recent 
EPVT. In this chapter we describe our experience with this treatment modality.
chapter 7. In almost all patients with chronic EPVT biliary abnormalities can be found. In 
only a few patients this will lead to symptomatic manifestations [12, 13]. In this chapter 
we describe incidence and clinical outcome of non- cirrhotic patients with symptomatic 
portal biliopathy seen at our hospital.
chapter 8. Summary and discussion
14 Chapter 1
reFerences
 [1] De Franchis R. Revising consensus in portal hypertension. Report of the Baveno V consensus 
Workshop on methodology of diagnosis and therapy in Portal Hypertension. J Hepatol. Milano: 
University of Milano 2010.
 [2] Henderson JM, Gilmore GT, Mackay GJ, Galloway JR, Dodson TF, Kutner MH. Hemodynamics dur-
ing liver transplantation: the interactions between cardiac output and portal venous and hepatic 
arterial flows. Hepatology. 1992 Sep; 16(3): 715-8.
 [3] Lebrec D, Bataille C, Bercoff E, Valla D. Hemodynamic changes in patients with portal venous 
obstruction. Hepatology. 1983 Jul-Aug; 3(4): 550-3.
 [4] Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor 
V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors as-
sociated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. 
Blood. 2000 Oct 1; 96(7): 2364-8.
 [5] Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med. 2001 Dec 6; 345(23): 
1683-8.
 [6] Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for throm-
bophilia in extrahepatic portal vein obstruction. Hepatology. 2005 Mar; 41(3): 603-8.
 [7] Egesel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y. The role of natural anticoagulant 
deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin 
Gastroenterol. 2000 Jan; 30(1): 66-71.
 [8] Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F 
mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb 
Haemost. 2007 Jan; 5(1): 55-61.
 [9] Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, et al. Current outcome of 
portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology. 
2001 Feb; 120(2): 490-7.
 [10] Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal 
venous obstruction. Q J Med. 1979 Oct; 48(192): 627-39.
 [11] Cohen J, Edelman RR, Chopra S. Portal vein thrombosis: a review. Am J Med. 1992 Feb; 92(2): 
173-82.
 [12] Khuroo MS, Yattoo GN, Zargar SA, Javid G, Dar MY, Khan BA, et al. Biliary abnormalities associated 
with extrahepatic portal venous obstruction. Hepatology. 1993 May; 17(5): 807-13.
 [13] Khare R, Sikora SS, Srikanth G, Choudhuri G, Saraswat VA, Kumar A, et al. Extrahepatic portal ve-
nous obstruction and obstructive jaundice: approach to management. J Gastroenterol Hepatol. 
2005 Jan; 20(1): 56-61.
chapter 2
non-cirrhotic non-malignant portal vein thrombosis: 
a review on the management of non-cirrhotic non-
malignant portal vein thrombosis and the concurrent 
portal hypertension complications in adults
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AbsTrAcT
background: Extrahepatic portal vein thrombosis (EPVT) is an important cause of non-
cirrhotic portal hypertension throughout the globe.
Aim: To provide an update on recent advances in the aetiology and management of 
acute and chronic non-cirrhotic non- malignant EPVT.
method: A Pubmed search was performed to identify relevant literature using search 
terms including ‘portal vein thrombosis’, ‘variceal bleeding’ and ‘portal biliopathy’.
results: Myeloproliferative disease is the most common risk factor in patients with 
non-cirrhotic non-malignant EPVT. Anticoagulation therapy for at least three months 
is indicated in patients with acute EPVT. However, in patients with EPVT due to a pro-
thrombotic disorder, permanent anticoagulation therapy has been recommended. The 
most important complication of EPVT is esophagogastric variceal bleeding. Endoscopic 
treatment is the first- line treatment for variceal bleeding. In several of the patients with 
EPVT biliopathy changes on ERCP have been reported. Dependent on the persistence of 
the biliary obstruction treatment can vary from ERCP to hepaticojejunostomy.
conclusion: Prothrombotic disorders are the major cause of non-cirrhotic, non-
malignant EPVT. Anticoagulation therapy is warranted in these patients. The prognosis 
of patients with non- cirrhotic non- malignant EPVT is good, and is not determined by 
portal hypertension complications but mainly by underlying causes of thrombosis.
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inTroducTion
Extrahepatic portal vein thrombosis (EPVT) is an important cause of non-cirrhotic portal 
hypertension throughout the globe. The aetiology of EPVT is heterogeneous and both 
local and systemic risk factors can be involved. Primary local risk factors for EPVT are 
cirrhosis, hepatobiliary malignancies and pancreatitis.[1, 2] Myeloproliferative disorders 
and prothrombotic genetic defects are the major systemic risk factors for EPVT. [3] 
The most important complication of EPVT is esophagogastric variceal bleeding with a 
reported mortality rate of 1.0 to 20%.[1, 2, 4-7]
AcuTe PorTAl Vein Thrombosis
Acute EPVT is characterised by a sudden formation of a thrombus within the portal vein, 
which leads to a complete or partial obstruction of the portal vein.
Patients with acute EPVT may experience a sudden onset of right upper abdominal 
or lumbar pain, but symptoms can also be non-specific or absent. Partial obstruction 
seems to be associated with fewer symptoms, than acute complete obstruction where 
features of intestinal congestion as permanent abdominal pain and diffuse thicken-
ing of the intestinal wall or an ileus can be present. Fever and ascites, usually in small 
quantities and of transient character, may be present. All these manifestations of acute 
EPVT are completely reversible, provided that the thrombus is limited to the portal vein. 
When the thrombosis extends into the mesenteric venous arches, intestinal ischaemia 
and later, infarction can occur.[8] Liver enzymes and bilirubin are usually normal or only 
mildly disturbed in patients free of liver diseases.[9] For most patients, in whom EPVT is 
suspected, diagnosis can be established by non-invasive imaging techniques, including 
Color Doppler- ultrasonography, CT-scan and MRI. Color Doppler-ultrasonography is the 
least expensive method, but the sensitivity and specificity are affected by inter-patient 
variability and expertise of a given radiologist.[10] CT-scan and MRI can provide more 
additional information on adjacent organs, vascular status, and extension of the throm-
bus. Once acute EPVT has been diagnosed, the cause of EPVT should be elucidated. In 
about 30% of the patients with acute EPVT a local risk factor can be identified and in 
70% a systemic risk factor can be found. [11-16] Local risk factors are mainly infectious 
and inflammatory diseases, such as diverticulitis, appendicitis, pancreatitis, cholecys-
titis, cholangitis and inflammatory bowel diseases. But also abdominal trauma and 
surgery, especially splenectomy, can cause EPVT. The latter is mainly seen in patients 
with myeloproliferative diseases and rarely in patient with lymphoma or splenic trauma.
[17] An acquired or inherited prothrombotic disorder can be identified in the majority 
of patients . (Table 1) Concurrence of either acquired or inherited prothrombotic dis-
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orders is common.[7, 12]Therefore extensive investigation of prothrombotic disorders 
is recommended. Frequently, EPVT is the first manifestation of a myeloproliferative 
disease, which is the major cause of EPVT and can be identified in at least 25- 30% of the 
patients[11, 12, 18]. It is often problematic to diagnose an underlying myeloproliferative 
disorder in patients with EPVT; clinical and haematological parameters usually yield 
insufficient information. The JAK2 V617F has recently been reported to represent, a reli-
able and non-invasive molecular tool and can be used as an additional diagnostic tool 
for identifying myeloproliferative disorders.[19, 20]
Treatment of acute EPVT aims to recanalize the obstructed veins and prevent exten-
sion of the thrombus. Once the diagnosis has been established anticoagulant treatment 
is indicated. The current recommendation is to continue oral anticoagulation for a 
period of at least three months. [21] In patients with a prothrombotic disorder life-long 
anticoagulant therapy should be considered. Although there are several case reports 
and reports of small series indicating that procedures as thrombectomy and local or 
systemic thrombolysis may be successful, the place of these invasive procedures is as 
yet uncertain. Also considering the risk of major procedure related complications, in 
one report in up to 60% of the cases, most centers tend to choose a more conservative 
therapeutic strategy. [22]
Table 1. Thrombotic risk factors in patients with extrahepatic portal vein thrombosis
Thrombotic risk factor prevalence of risk factor in patients with EPVT
%
systemic
Myeloproliferative disease 14 – 35
Antiphospholipid syndrome 6 – 11
Factor V Leiden mutation 3 – 8
Factor II gene mutation 3– 22
Protein C deficiency* 0 – 7
Protein S deficiency* 2 – 30
Antithrombin deficiency* 1 – 5
Recent oral contraceptive use 21 – 48
local
Inflammatory diseases/ 5 - 17
Infectious diseases*
Surgery* 5 - 30
Trauma 0 - 3
Cirrhosis 17- 22
Malignancies 24
* different definitions are used
[7, 11-13]
Non-cirrhotic non-malignant EPVT: a review 19
chronic PorTAl Vein Thrombosis
Chronic portal vein thrombosis usually leads to the formation of portal cavernoma. Cav-
ernous transformation refers to the development of a network of porto-portal collateral 
veins bypassing the site of obstruction. Non-invasive imaging as ultrasound, CT-scan or 
MRI, can easily make a diagnosis of portal cavernoma.
Systemic causes are similar in prevalence as in acute EPVT.[23] However local risk fac-
tors can be missed in patients with chronic EPVT. The clinical presentation of chronic 
EPVT is mainly characterised by manifestations of portal hypertension such as esopha-
gogastric varices and hypersplenism. Encephalopathy and ascites are uncommon fea-
tures in patients with chronic EPVT without underlying cirrhosis. In contrast to variceal 
bleeding in patients with cirrhosis the risk of developing liver failure and death is rare 
and mortality is primarily related to medical conditions, which are often the cause of 
EPVT, rather than to variceal bleeding. [7] Serum liver tests are typically normal or near 
normal. However, when cholestatic features are present abnormalities of the extra- and 
intra-hepatic bile ducts should be considered.
The treatment of chronic EPVT aims to reverse manifestations of portal hypertension 
such as gastrointestinal bleeding (see variceal bleeding). There is no consensus on the 
indication for anticoagulant therapy. However in patients with a persistent prothrom-
botic state, anticoagulant therapy can be considered.
VAriceAl bleeding
More than 85 to 90% of patients with chronic EPVT have esophageal varices and 30 to 
40% percent have concomitant gastric varices.[1] Also, rectal, duodenal and other types 
of ectopic varices may occur. The size of esophageal varices and to a lesser degree, initial 
presentation with gastroesophageal bleeding are independent predictors for rebleed-
ing both in patients with EPVT as in patients with cirrhosis[4, 24]. Although variceal 
bleeding is the most important complication, EPVT-related mortality appears primarily 
determined by other causes than variceal bleeding[7, 25].
Prophylaxis: there are no controlled studies of β-adrenergic blockade or endoscopic 
therapy as primary prophylaxis for esophageal variceal bleeding in patients with EPVT. 
It has only been speculated that in patients with large esophageal varices β-adrenergic 
blockade or endoscopic therapy can be carried out and reduce the incidence of first 
bleeding as they are for patients with cirrhosis[26]. Two retrospective studies have 
suggested that β-adrenergic blockade may play a role in secondary prophylaxis as they 
reduce the risk of rebleeding and improve survival after EPVT-induced variceal haemor-
rhage[4, 27]. However, there is as yet insufficient evidence to recommend wide spread 
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use of β-adrenergic blockade for secondary prophylaxis [21]. Endoscopic therapy is safe 
and have been found to be effective in prevention of rebleeding[25].
Treatment of active variceal bleeding: endoscopic injection sclerotherapy (EIS) and 
endoscopic variceal ligation (EVL) of esophagogastric varices have been found to be 
effective in the control and prevention of variceal haemorrhage[25, 28-34]. Since 1986 
EVL has mainly been used as endoscopic method for treating esophageal varices. EIS 
is often reserved for the treatment of active gastric variceal bleeding. Although there 
are limited data on the use of vasoactive agents for the control of active bleeding in 
patients with EPVT, these drugs are usually recommended [21]. There is evidence that 
TIPS is successful, when technical applicable.[35-37] Unsuccessful TIPS placement are 
mainly due to fact that the lumen of the thrombosed portal vein is no longer catheteriz-
able or the fragile cavernomatous vein could not be dilated without risk of rupture. If 
endoscopic treatment fail a surgical shunt can be considered [21]. (Table 2). Both total 
and selective shunts have been used[38-40].However, nowadays selective shunts, as the 
(distal) splenorenal shunt, are the preferred type of shunt surgery, due to a low risk of 
encephalopathy and durable decompression. [41, 42] The main problems that occur with 
these procedures is per operative bleeding due to existence of collaterals, extension of 
the thrombosis into the splenic and mesenterial veins and thrombosis of the shunt. It 
Table 2. Treatment recommendations of EPVT
Treatment indication
Thrombotic obstruction
Anticoagulants acute EPVT
chronic EPVT if a prothrombotic disorder is present
Thrombolysis and thrombectomy not recommended (high complication rate)
Variceal bleeding
Endoscopic treatment active variceal bleeding
secondary prophylaxis for rebleeding
Vasoactive agents can be considered in patients with active variceal bleeding
β-adrenergic blockade not yet recommended (insufficient evidence)
TIPS if endoscopic treatment fails and if technical applicable 
(little evidence)
Surgical shunt if endoscopic treatment fails
Portal biliopathy
Sphincterotomy, balloon dilatation, jaundice/ cholangitis/ biliary stenosis/ bile duct stones
endoprosthesis
Portosystemic shunt persistent biliary obstruction despite endoscopic 
treatment
Hepaticojejunostomy persistent biliary obstruction despite a portosystemic 
shunt
[21]
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is suggested that shunt thrombosis depends mainly on sufficient caliber and throm-
bus free veins, which are suitable to create a tension free and wide anastomosis.[43] 
Splenectomy alone is an inappropriate operation for the treatment of hypersplenism 
and portal hypertension.[38, 44] It does not prevent variceal bleeding and destroys the 
opportunity to use the splenic vein for a shunt. Especially in patients with non-cirrhotic 
portal hypertension and in patients with myeloproliferative disorders, where the spleen 
may become a place for extramedullary marrow formation, one should preserve the 
spleen, whenever possible.[43]
PorTAl bilioPAThy
Portal biliopathy is defined as abnormalities of the extrahepatic and intrahepatic bile 
ducts due to impressions of porta-portal collaterals in patients with portal hypertension 
secondary to EPVT. [45-48] (Figure 1). In 80-100% of the patients with EPVT biliary ab-
normalities, such as indentations, marked angles, stenosis and biliary stones have been 
reported. The biliary abnormalities involve the large bile ducts, especially the common 
bile duct and the main left hepatic duct. The small bile ducts remain normal as liver 
biopsy does not demonstrate evidence of ductopenia or ductular proliferation.
The left hepatic duct is involved more often; this may due to formation of prominent 
collateral veins where the umbilical vein joins the left branch of the portal vein. The bili-
Hoofdstuk 2 figure 1
Figure 1. Portal biliopathy in a patient with chronic portal vein thrombosis. ERCP showing a sharp angled 
CBD with impressions (arrows)
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ary abnormalities are common in EPVT because paracholecystic and paracholedochal 
form the porto-portal collaterals to bypass the obstructed segment of the portal vein. 
The cause of the biliary abnormalities can not only be explained by compression of 
the bile ducts due to the collaterals but also by ischemic injury of the bile ducts due 
to thrombosis of veins draining the bile duct.[45] Portal biliopathy is despite its com-
mon occurrence, rarely symptomatic. [47] However biochemical changes can be seen. 
Symptomatic patients are usually adults, which may indicate that portal biliopathy is a 
slowly progressive disease. Portal biliopathy can be diagnosed with ERCP or MRCP and 
can mimic the bead-like appearance of primary sclerosing cholangitis.[49] In patients 
with cholangitis and choledocholithiasis biliary stenting, balloon dilatation, sphincter-
otomy and stone extraction can give symptomatic relief. For dominant biliary strictures 
and endoscopic failures, portosystemic shunting can be considered, which can lead 
to amelioration of the biliary obstruction. In patients with persistent obstruction, he-
paticojejunostomy may be needed to treat the biliary obstruction. (Table 2). Prior to the 
hepaticojejunostomy a portosystemic shunt can be made, to have better access to the 
region.[50]
conclusion
Thrombotic risk factors, especially myeloproliferative disorders are the main cause of 
non-cirrhotic EPVT. Extensive investigation for these risk factors is recommended, also 
because concurrence of acquired and inherited prothrombotic disorders is common. 
[7, 12] In patients with acute EPVT oral anticoagulation for at least three months is 
warranted. In patients with chronic EPVT, due to a prothrombotic disorder, permanent 
oral anticoagulation therapy can be considered. The most important complication of 
EPVT is variceal bleeding. Endoscopic treatment is the first-line treatment both for active 
variceal bleeding and for secondary prophylaxis. If endoscopic treatment fails, a TIPS or 
a selective surgical shunt should be considered. The use of β-adrenergic blockade as pri-
mary or secondary prophylaxis is not yet recommendable, due to insufficient evidence.
Portal biliopathy can play a role in the long-term outcome, because of its slowly pro-
gressive character. If endoscopic treatment fails a portosystemic shunt with if necessary 
a hepaticojejunostomy can be considered.
The prognosis of patients with EPVT is good. Mortality is mainly determined by con-
comitant diseases which led to EPVT and not by complications of portal hypertension.
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AbsTrAcT
background: Esophagogastric variceal bleeding is the most important complication of 
extrahepatic portal vein thrombosis (EPVT), and is usually treated endoscopically. Little 
is known on the prognosis of these patients.
objectives: To investigate the long-term clinical outcome and efficacy of endoscopic 
treatment in patients with esophagogastric variceal bleeding secondary to EPVT.
design: Retrospective observational study.
settings: Single university center.
Patients: Twenty-seven consecutive patients with esophagogastric variceal bleeding 
secondary to non-cirrhotic, non-malignant EPVT, who underwent endoscopic treatment 
between 1982 and 2005.
interventions: endoscopic band ligation and/ or endoscopic sclerotherapy.
main outcome measurements: overall rebleeding risk, overall survival, complications 
of the endoscopic procedures and predictive values of rebleeding. Analyses were per-
formed by Kaplan Meier method and univariate Cox regression.
results: All patients were followed after their first endoscopic treated variceal bleeding. 
A total of 241 endoscopic procedures were performed. In all patients, initial control of 
bleeding was obtained. Overall re-bleeding risk was 23% (95% CI 0-24) at 1- year and 
37% (95% CI 43-83) at 5-years. Extension of thrombosis into the splenic vein and the 
presence of fundal varices were significant predictors of re-bleeding, with a nearly 5-fold 
increased risk for EPVT patients with fundal varices at the time of the first variceal hem-
orrhage (HR= 5.07; p= 0.01). A porto-systemic shunt procedure was performed in five 
patients, in four for variceal bleeding and in one for refractory ascites. Seven patients 
died, not one due to variceal bleeding. Overall 5- and 10-year survival was 100% and 
62% (95% CI 38%-96%), respectively.
limitations: retrospective design.
conclusion: In patients with variceal bleeding secondary to EPVT endoscopic treat-
ment, in particular band ligation, appears safe and effective. EPVT-related mortality is 
primarily determined by other causes than variceal bleeding.
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inTroducTion
Extra-hepatic portal vein thrombosis (EPVT) is throughout the globe an important 
cause of non-cirrhotic portal hypertension. The aetiology of EPVT is heterogeneous. 
Primary risk factors for EPVT are cirrhosis, hepatobiliary malignancies and pancreatitis. 
In addition, systemic risk factors for thrombosis, such as myeloproliferative disorders 
and prothrombotic genetic defects, have been identified as major risk factors for EPVT. 
Esophagogastric variceal bleeding is the most important complication of EPVT1. In one 
study the incidence rate of esophagogastric variceal bleeding in patients with EPVT was 
35%. Fifty-eight percent of these patients had a recurrent bleeding1-6. Gastrointestinal 
bleeding caused by portal hypertension in patients with EPVT has been reported to 
cause death in 1.5 to 20% of the patients1-5. Endoscopic treatment is the first line in-
tervention in patients with bleeding esophagogastric varices. Since 1986 endoscopic 
variceal ligation (EVL) has increasingly being used as an alternative endoscopic method 
for treating esophageal varices6. EVL is as effective as endoscopic injection sclerotherapy 
(EIS) but has less complications6-9. In contrast to endoscopic treatment of variceal bleed-
ing in patients with cirrhosis, little is known about the outcome of this treatment in adult 
patients with EPVT.
In the current cohort study we investigated the efficacy of endoscopic treatment and 
clinical outcome as well as predictors of rebleeding in adult patients with esophagogas-
tric variceal bleeding due to non- cirrhotic, non- malignant EPVT.
PATienTs And meThods
design of the study
Patients were identified by means of a search in the computerised patient registration 
system of our clinic, which serves a tertiary referral function. All adult patients identi-
fied between January 1982 and October 2005 were enrolled if (1) extra-hepatic portal 
vein thrombosis was documented (2) cancer and/ or cirrhosis were absent, (3) variceal 
bleeding was present and (4) endoscopic treatment was performed. For all patients a 
standardised clinical record form for specific clinical data, obtained from the medical 
charts, was completed.
From a total of 195 patients with EPVT, 27 patients were included in this study. Patients 
were excluded for the following reasons: 63 patients had cirrhosis, 49 patients had ma-
lignancies, 7 patients had developed EPVT after liver transplantation and in 49 patients 
variceal bleeding did not occur.
Among the 27 patients in the cohort, follow-up lasted from the time of endoscopic 
treatment of variceal bleeding to either November 2005 or death, whichever came first.
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diagnostic assessment
Diagnostic criteria for EPVT were partial or complete obstruction of the extrahepatic 
portal vein, as documented by appropriate radiological imaging, such as Doppler ul-
trasonography, computed tomography, magnetic resonance imaging, venography and 
angiography. Cirrhosis was excluded by a combination of absence of biochemical evi-
dence of liver failure, absence of cirrhosis at imaging and in 18 cases absence of cirrhosis 
on liver biopsy.
Gastroesophageal varices were graded according to the following classification10: 
grade I, varices flattened by insufflation; grade 2, varices not flattened by insufflation; 
grade 3, confluence of varices not flattened by insufflation; grade 4, grade 3 with red 
marks. The aim of endoscopic treatment was either to stop the bleeding or to reach 
variceal eradication. Endoscopic sclerotherapy was performed with flexible endoscopes 
and a 25-gauge disposable injection needle. Ethanolamine or 2% ethoxysclerol were 
used as sclerosing agents. Persistent variceal bleedings not responsive to injections of 
sclerosing agents were treated with additional local injections of thrombin. Injections 
were intentionally intravascular with a volume not exceeding 1 ml. Endoscopic ligation 
was performed using an endoscope with a multi-band ligator.
Variceal eradication was defined as nonvisualization of varices or grade I varices. 
Variceal (re)bleeding was defined according to internationally accepted criteria of 
the Baveno consensus meetings11-13. Variceal bleeding was defined as: active variceal 
bleeding seen endoscopically, signs of recent variceal bleeding, varices without other 
bleeding sources with a history of haematemesis and/ or melaena or blood present in 
the stomach. Rebleeding was defined according to Baveno consensus II as13: evidence of 
any bleeding after at least 48 hours.
Data on diagnosis, endoscopic procedures and outcome were collected by systematic 
review of the charts and endoscopy reports.
sTATisTics
Statistical analysis was performed using the Kaplan Meier method for overall and re-
bleeding free survival. Due to the small amount of events univariate Cox regression 
models, stratified for number of re-bleedings, were used to determine significant predic-
tors of re-bleeding.
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resulTs
Twenty-seven patients were enrolled in this study. The main baseline characteristics are 
presented in table 1. EPVT was initially demonstrated by means of ultrasound (n=14), 
computed tomography (n=7), venography (n=4), magnetic resonance imaging (n=1) 
and angiography (n=1). The median duration of follow up after the first bleeding epi-
sode was 8.6 years (range 0.7- 22.1 years). No patient was lost to follow up.
Variceal bleeding
In the 27 consecutive patients a total of 241 endoscopic procedures were performed. 
Of these 241 endoscopic procedures 42 (17%) endoscopic procedures were performed 
for variceal bleeding (Figure 1). Of these 42 procedures, 27 (64%) were done for initial 
treatment of variceal bleeding. In 18 patients (67%) the first variceal bleeding was due 
to esophageal varices, in 9 (33%) patients due to gastric varices. In one patient variceal 
bleeding occurred due to duodenal variceal bleeding which was treated with sclero-
therapy. In 2 (7%) patients with an active variceal bleeding endoscopic therapy was not 
successful. In these patients hemostasis was achieved by construction of a mesocaval 
shunt and placement of a balloon tamponade.
Variceal eradication
Variceal band ligation (n=11) was performed in 33 sessions, sclerotherapy (n=20) was 
performed in 93 sessions and in one session both endoscopic modalities were performed. 
Overall, five patients were treated with both endoscopic modalities for achieving and 
maintaining variceal eradication. A mean of five endoscopic procedures (range 1-11) per 
patient were needed for variceal eradication. In five patient variceal eradication was not 
Hoofdstuk 3 figure 1
27 first variceal 
bleeding
15 variceal 
rebleeding
42 variceal 
bleeding
127 intervention 
procedures for 
variceal erdication
72 no intervention 
procedures
199 endoscopy
241 endoscopic 
procedures
Figure 1. Study algorithm
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Table 1. Baseline Characteristics of the Patients
Variable at baseline N= 27 %
Sex
Male
Female
Median age (yrs)
Extension of thrombosis
7
20
48
25
75
-
- Portal vein 13 50
- Portal and splenic veins 3 11
- Portal and mesenterial veins 2 7
- Portal, splenic and mesenterial veins 9 32
Underlying cause
- Myeloproliferative disease
 - Polycythemia vera
 - Essential thrombocytosis
 - Myelofibrosis
 - Unclassified
- Infection
- Surgery
 - Splenectomy
 - Cholecystectomy
 - Gynaecologic procedure
 - Appendectomy
 - Other
- Other
 - Oral contraception
 - Smoking
 - History of thrombosis
 - Family history of thrombosis
10
2
3
3
2
3
3
2
2
1
1
7
5
4
4
36
7
11
11
7
11
11
7
7
7
4
25
18
14
14
Varices grade
- Grade I
- Grade II
- Grade III
- Grade IV
1
1
8
14
4
4
29
50
Varices location
- Esophagus
- Esophagus and cardia
- Esophagus and fundus
- Esophagus, fundus and corpus
- Esophagus, cardia and fundus
12
6
4
1
3
43
21
14
4
11
Previous treatment
- Shunt placement
Signs and symptoms
- Splenomegaly
- Ascites
- Abdominal pain
1
12
6
13
4
43
21
46
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accomplished. All of these patients had grade II varices at last follow up. None of these 
patients developed a recurrence of variceal bleeding.
Variceal rebleeding
Variceal rebleeding was observed in 37% (n= 10) of the patients. In seven of these ten 
patients, variceal rebleeding occurred due to gastric varices and in three due to esopha-
geal varices. In six patients variceal rebleeding occurred after sclerotherapy, and in four 
patients after ligation. Overall re-bleeding risk was 23% (95% CI 0- 24) at 1-year, 37% 
(95% CI 43- 83) at 5-years and 44% (95% CI 34-78) at 10-years (Figure 2). Using univariate 
analysis we studied different variables to identify significant independent predictors of 
re-bleeding (see Table 2). Extension of thrombosis into the splenic vein and the presence 
of fundal varices appeared to be predictors of re-bleeding, with an approximately 5-fold 
risk for EPVT patients with concomitant splenic vein thrombosis and fundal varices (HR= 
4.21 p=0.03 and HR= 5.07 p=0.01 respectively).
shunts
A porto-systemic shunt procedure was performed in five patients for the following rea-
sons: ongoing active variceal bleeding despite endoscopic sclerotherapy (n=1), variceal 
No at risk
27         16        14         12  10         5     4           2
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Figure 2. Kaplan- Meier curve showing the percentage patients free of esophagogastric variceal 
rebleeding
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Table 2. Predictive values for rebleeding
Variable at baseline N= 27 rebleeding
n= 10
HR 95% CI
Lower – upper
P p-value
Age
Male
Female
Site of thrombosis:
27
7
20
10
3
7
1.01
1
0.65
0.97 – 1.06
0.17 – 2.52
0.55
0.53
 Portal vein 13 3 1 0.36
 Portal and splenic veins 3 2 3.59 0.59 – 21.66 0.16
 Portal and mesenterial veins 2 0 0.99
 Portal, splenic and mesenterial veins 9 5 3.41 0.81 – 14.35 0.10
Splenic vein thrombosis
 Absent 15 3 1
 Present 12 7 4.21 1.08 – 16.4 0.03
Mesenterial vein thrombosis
 Absent 16 5 1
 Present 11 5 1.67 0.48 – 5.79 0.4
Ascites
 Absent 16 6 1
 Present 8 4 1.79 0.50 - 6.41 0.37
Site of varices
- Limited to esophagus
- Esophagus and stomach*)
12
14
4
6
1
1.25 0.35 – 4.42 0.73
  Fundus 8 6 5.07 1.40 – 18.4 0.01
  Cardia 6 0 0.31 0.06 – 1.50 0.11
  Corpus 1 1
Cavernoma
 Absent 14 6 1
 Present 12 4 0.95 0.27 – 3.40 0.94
Splenomegaly
 Absent**) 6 2 1
 Present 18 7 1.95 0.41 – 1.95 0.40
After initial bleeding
 ICU admission
  Absent 20 6 1
  Present 5 3 0.41 0.10 – 1.72 0.20
 Packed cells given
  No 10 4 1
  Yes 15 3 1.97 0.49 – 7.98 0.33
 Thrombopenia
  Absent 21 6 1
  Present 5 3 0.44 0.12 – 1.58 0.20
*) Combined presence occurred in 4 patients
**) Also includes patients who underwent splenectomy
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rebleeding (n=2) and refractory ascites (n=1); in one patient the therapeutic algorithm 
of endoscopic therapy as preferred standard treatment was not followed for unknown 
reasons and a distal splenorenal shunt was constructed. Shunt occlusion was seen in 
three of the five patients. In two of them this resulted in variceal rebleeding.
medication
Four patients were treated with a vasoactive agent for the first variceal bleeding and one 
patient was treated with a vasoactive agent for rebleeding. A total of five patients were 
treated with oral anticoagulation therapy, three of them were already on this treatment 
at the time of the first variceal bleeding. In only one patient oral anticoagulation therapy 
was discontinued after the index variceal bleeding occurred. In none of the five patients 
a variceal rebleeding occurred. A total of ten patients were treated with β-adrenergic 
blocking agents. Six of them were already on treatment with β-adrenergic blocking 
agents, for prevention of variceal bleeding, at the time of baseline hemorrhage. In three 
of the ten patients a variceal rebleeding occurred. In all of these patients fundal varices 
were present and β-blocking therapy was started before the index bleeding. In patients 
started with β-blocking therapy after endoscopic treatment no rebleeding occurred. 
From the twelve patients that had developed ascites, ten patients were treated with 
diuretics.
survival
Seven patients died. Of these seven deaths that occurred none was caused by variceal 
bleeding. Causes of death were: myelofibrosis (n=2), infection (n=2), gastro-intestinal 
bleeding due to a pill induced esophageal ulcer (n=1), cerebellar hematoma accom-
panied by disseminated intravasculair coagulation (n=1), and decompensated cirrhosis 
(n=1). The latter patient developed cirrhosis 13 years after the diagnosis EPVT was estab-
lished. Early biopsies of the liver did not show any signs of cirrhosis. Overall survival was 
100% at five years and 62% (95% CI 38- 96) at 10-years (Figure 3).
complications
In one patient a symptomatic esophageal stenosis occurred, after endoscopic treatment 
with sclerotherapy, which needed endoscopic dilatation. One patient died of a gastro-
intestinal bleeding due to a pill induced esophageal ulcer eight years after endoscopic 
treatment with sclerotherapy.
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discussion
In this study we investigated the clinical outcome and predictors of rebleeding in pa-
tients with esophagogastric variceal bleeding due to non-cirrhotic EPVT. We found that 
the rebleeding rate was 23% after the first year and decreased over time with maintained 
endoscopic follow-up. The presence of fundal varices and extension of thrombosis into 
the splenic vein were predictors of rebleeding. Mortality was determined by other 
causes than variceal (re)bleeding or endoscopic treatment complications. As of yet, 
studies on efficacy of endoscopic treatment of variceal bleeding and predictors of re-
bleeding in adult patients with non cirrhotic portal hypertension are scarce. In general, 
endoscopic treatment of variceal bleeding appears successful14-16. One study reported 
high recurrence of variceal bleeding after endoscopic treatment. However, this study 
started in the late fifties, was designed to investigate porto-systemic shunting rather 
than endoscopic therapy and details on the endoscopic interventions are lacking17. The 
observed rate of variceal rebleeding at 1 year was 23% in our study, which is also sub-
stantially lower than the 36-50% rebleeding risk at 1 year reported for historic controls 
with cirrhosis18,19. Over time, the rate of variceal rebleeding decreased, indicating that 
in these patients variceal eradication appears feasible and is associated with an almost 
complete protection against rebleeding. Previously, the size of esophageal varices and 
to a lesser degree, initial presentation with gastroesophageal bleeding were found to be 
27            26             18 12            11              9
No at risk
Due to variceal bleeding
Due to other causes
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Figure 3. Kaplan-Meier curve showing the percentage of patients dying from variceal bleeding an other 
causes
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independent predictors for rebleeding both in patients with EPVT and cirrhosis1,20. In our 
study we found that the extension of thrombosis into the splenic vein as the presence of 
fundal varices were significant predictors of rebleeding. We also found that in 67% of our 
patients rebleeding was caused by gastric varices. These findings could be explained by 
gastric hemodynamic changes after endoscopic therapy, because prophylactic variceal 
eradication with EVL and EIS may increase both the incidence and the severity of fundal 
varices formation21. Since gastric varices are difficult to eradicate by endoscopy and thus 
often the source of rebleeding, theoretically one could reconsider the use of β-blocking 
agents as secondary prophylaxis, in particular for those with extensive fundal varices 
at the time of the index bleeding. Two studies indeed suggested that β-blockers may 
reduce the risk of rebleeding after EPVT-induced variceal hemorrhage1,22. This concurs 
with our findings that in patients started with β-blockers after endoscopic treatment 
no rebleeding occurred. However, there is as yet limited evidence to recommend wide 
spread use of β-blockers for secondary prophylaxis13. The absence of variceal (re)bleed-
ing related mortality in our patients with EPVT contrasts the hospital related mortality 
of 20% in cirrhotic patients with variceal bleeding23. This difference is largely caused by 
the fact that variceal bleeding in cirrhotic patients may be difficult to control due to an 
impaired coagulation and that these patients are at increased risk of life-threatening 
infections24. Regarding the causes of death our study confirms earlier findings that 
survival in patients with EPVT is primarily determined by other - sometimes underlying 
- diseases of thrombosis rather than variceal (re)bleeding itself25.
Several biases might have been introduced in the current retrospective study. Firstly, 
our hospital is a tertiary referral center and selection bias may have led to under- or over- 
representation of certain patient categories. Secondly, during the long study period (23 
years) a shift in the treatment modalities, in particular the transition from sclerotherapy 
to band ligation, may have influenced our results. Due to the design of this study, the 
limited number of patients treated with band ligation and the fact that some patients 
were treated with both endoscopic procedures over time, comparison between the two 
modalities and differences in outcomes such as rebleeding rates was not possible. In 
children and adolescents with EPVT, endoscopic variceal ligation was superior to sclero-
therapy, particularly in lowering the complication rate, rebleeding and mortality26. The 
limited number of patients treated with band ligation in our study could therefore have 
led to overestimation of rebleeding. In current practice almost exclusively band ligation 
is used. In summary, our data indicate that endoscopic treatment, is a safe and effective 
primary treatment modality for variceal bleeding in patients with EPVT. Rebleeding rate 
was low and mainly caused by gastric varices. Most important risk factors for rebleed-
ing were the extension of thrombosis into the splenic vein and the presence of fundal 
varices. In contrast to patients with cirrhosis, EPVT-related mortality appears primarily 
determined by other causes than variceal bleeding.
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AbsTrAcT
background and Aims: The clinical significance of ascites in patients with extrahepatic 
portal vein thrombosis (EPVT) has been poorly defined. The aim of this study was to 
assess the frequency, natural history and prognostic implication of ascites in patients 
with EPVT, and to identify risk factors for this complication.
methods: Single-center retrospective study of all consecutive patients diagnosed with 
non- cirrhotic non- malignant EPVT between 1985 and 2005. The main outcome was 
survival for patients with and without ascites at presentation.
results: One hundred and three patients (35% males; median age 43 (range 16– 83) 
years) were included and followed for a median time of 5.2 (range 0.9 – 32.5) years. 
Twenty-nine (28%) had ascites at the time of diagnosis. Ascites was associated with 
increased mortality (p= < 0.01). There was no correlation between the presence of 
ascites and the extension of the thrombus into the large splanchnic veins, the duration 
of thrombosis or the presence of gastrointestinal bleeding.
conclusion: Ascites is present in a substantial proportion of adults presenting with non-
cirrhotic non- malignant EPVT. Ascites is a significant and independent prognostic factor 
and associated with a decreased long-term survival.
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inTroducTion
Extrahepatic portal vein thrombosis (EPVT) is the second cause of portal hypertension 
worldwide. Main causes of non- cirrhotic non- malignant portal vein thrombosis are my-
eloproliferative diseases and inherited or acquired thrombophilic disorders[1-4]. Portal 
hypertension often develops as a result of EPVT. Ascites is a common complication of 
portal hypertension in cirrhotic patients [5-7]. Twenty percent of the cirrhotic patients 
have ascites at the time of diagnosis, while 30% and 50% will develop ascites by 5 and 10 
years, respectively [5, 8]. In children with EPVT ascites has been described in association 
with gastrointestinal hemorrhage and / or surgery and appeared to be transient [9]. In 
young adult patients with EPVT and a history of gastrointestinal hemorrhage ascites can 
also develop spontaneously with an annual incidence rate of 20% [10]. In contrast to 
ascites in cirrhotic patients which is associated with an increased risk for mortality and 
associated with an expected survival below 50% after 5 years, little is known about the 
morbidity and mortality of adult patients with non- cirrhotic non- malignant EPVT and 
ascites [11, 12]. In the current cohort study we investigated the incidence and clinical 
outcome of ascites in adult patients with non- cirrhotic non- malignant EPVT.
PATienTs And meThods
design of the study
From 1985 until 2009 all consecutive patients from our hospital with a non- cirrhotic non- 
malignant EPVT were enrolled in this study. Date of diagnosis was defined as the first date 
EPVT was found on radiological imaging either elsewhere or in our tertiary referral center. 
Patients who were referred to our clinic underwent radiological imaging in our hospital 
to confirm the diagnosis. In these cases data with regard to the presence of ascites at 
diagnosis were retrieved from the referring hospital. Follow up started after the diagnosis 
EPVT was established and lasted until either December 2009 or death, whichever came 
first. For all patients a standardized clinical record form with data on diagnosis, ascites, 
treatment and outcome was collected by a systematic review of the medical charts.
diagnostic assessment
Patients with EPVT and previous or concurrent malignant disease, Budd-Chiari syn-
drome, veno-occlusive disease, liver transplantation or with concurrent heart failure at 
the time of diagnosis were excluded. Cirrhosis was excluded by liver biopsy and/or a 
combination of radiological imaging and biochemical tests. EPVT was classified accord-
ing to international consensus guidelines, namely obstruction of the extra-hepatic por-
tal vein, with or without involvement of the intrahepatic portal veins [9]. The diagnosis 
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of EPVT was based on radiological imaging using Doppler ultrasonography, computed 
tomography, magnetic resonance imaging or venography. EPVT was defined as chronic, 
when multiple hepatopetal collaterals, so called portal cavernoma or gastrointestinal 
varices were present. When these features were absent the presentation of EPVT was 
considered acute. Ascites was diagnosed by radiological imaging. Examination of the 
ascitic fluid was performed in case of clinical suspicion of bacterial peritonitis or if other 
causes of ascites than EPVT were suspected.
sTATisTics
Kaplan Meier method was used to calculate overall survival and the log-rank test was 
used for comparing groups. Determinants of survival and the effect of ascites were esti-
mated as a hazard ration (HR) and corresponding 95% confidence interval (CI) using Cox 
regression analysis adjusted for sex and age. Occurrence of ascites during follow-up was 
analysed as a time-dependent factor. Proportionality assumption was checked for each 
determinant and no significant division from proportionality was found. A p-value of 
< 0.05 was considered statistically significant. All statistical analysis were performed with 
the Statistical Package for Social Sciences for Windows, version 16.0 (SPSS, Chicago, IL).
resulTs
From a total of 113 patients presenting with non- cirrhotic non- malignant EPVT 103 
patients were included in this study. Ten patients were excluded due to lack of reliable 
data with regard to ascites at the time of diagnosis. The median age of those enrolled in 
the study was 43 years (range 16 – 83 years). The median duration of follow up was 5.2 
years (range 0.9 – 32.5 years). Baseline patient characteristics according to the presence 
of ascites at baseline are summarized in table I. Cirrhosis was excluded by liver biopsy 
in 39 patients.
At baseline and during follow up ascites was diagnosed in a total of 39 patients. 
Twenty-nine patients had ascites at the time of diagnosis and ten patients developed de 
novo ascites during follow up. The overall risk of developing ascites was 36% (95% CI 27-
45) at 1-year and 37% (95% CI 28-46) at 10- years (figure 1A). Diagnostic paracentesis was 
performed in fourteen patients. Examination of the ascitic fluid showed a serum-ascites 
albumin gradient ≥ 11 gr/ l in all cases. Bacterial peritonitis was diagnosed in three cases 
during follow up. In all the other patients the ascitic fluid showed no elevated absolute 
polymorphonuclear leukocyte count (< 250 cells/mm3) and bacterial cultures were 
negative.
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In the twenty-nine patients who had ascites at the time EPVT was diagnosed, throm-
bosis was seen in the portal vein only (n= 15), in the portal and splenic vein (n= 1), in 
the portal and superior mesenteric vein (n= 3) and in the portal, splenic and superior 
mesenteric vein(n= 10). EPVT was acute in six of 28 patients and chronic in 22 of 28 
patients. In one patient no description of acute or chronic EPVT was given.
Among the total group of 103 EPVT patients 33 (32%) had a myeloproliferative dis-
order (MPD). There was no significant correlation between the presence of ascites and 
other important baseline variables such as MPD, duration of thrombosis (acute versus 
Table 1. Baseline Characteristics of the 103 Patients
Variable at baseline Patients with ascites
n=29 (%)
Patients without ascites
n = 74 (%)
Sex (m/f ) 16/ 13 23 / 51
Age (yrs)1* 41 ± 16 (27 - 77) 43 ± 17 (16 - 83)
Duration of thombosis
- Acute
- Chronic
6 /28(21%)
22/28(79%)
28/68 (41%)
40/68 (59%)
Site of thrombosis
- Portal vein
- Portal and splenic veins
- Portal and mesenterial veins
- Portal, splenic and mesenterial veins
15/29 (52%)
1/29 (3%)
3/29 (10%)
10/29 (34%)
43/74 (58%)
7/74 (9%)
10/74 (14%)
14/74 (19%)
Underlying causes
- Inherited thrombophilia
- Acquired disorders
5/23 (22%)
22/29 (76%)
18/61 (30%)
55/74 (74%)
Acquired disoders
- Myeloproliferative disease
- Infection
- Surgery
13/29 (45%)
5/29 (17%)
3/29 (10%)
20/73 (27%)
16/74 (22%)
24/74 (32%)
Signs and symptoms
- Abdominal pain
- Splenomegaly
- Ascites
- Hepatomegaly
19/29 (66%)
19/25 (76%)
28/28 (100%)
2/27 (7%)
50/72 (69%)
36/67 (54%)
0/74 (0%)
9/74 (12%)
Varices
- Variceal bleeding (yes / no)
17/27 (63%)
9/27 (33%)
33/53 (62%)
14/59 (22%)
Blood hemoglobin (mmol/ L)2* 6.7 ± 1.5 (4.9 – 10.0) 7.7 ± 1.7 (4.3 – 13.8)
Platelet count (x 10E9/ L)3* 247 ± 239 (49 –1083) 267 ± 175 (31 – 888)
Bilirubin (μmol/L)4*
Aspartate transaminase (U/ L)5*
15 ± 19 (3 – 100)
33 ± 15 ( 7 – 57)
13 ± 35 (4 – 242)
27 ± 41 (3 – 284)
Alanine transaminase (U/ L)6* 28 ± 22 (9 – 111) 29 ± 43 (9 – 198)
Serum albumin (g/ L)7* 37 ± 8.0 (22- 48) 38 ± 7 (24 – 51)
Serum creatinin (μmol/ L)8* 69 ± 26 (44 – 170) 67 ± 56 (35 – 385)
APTT (sec)* 36 ± 17 (25 – 83) 32 ± 13 (3 – 88)
PT (sec)* 15 ± 2.2 (11 – 20) 16 ± 8.8 (10 – 57)
PTINR * 1.3 ± 0.5 (1.0 – 2.8) 1.3 ± 0.9 (1.0 – 4.3)
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chronic), the extension of thrombosis into any of the splanchnic veins or with concomi-
tant variceal bleeding.
The presence of ascites during follow up was diagnosed by radiological imaging in 
95 patients and by a laparoscopic procedure in one patient. In the patients a median of 
three (range 1-11) radiological imaging procedures were performed during follow-up. 
In 23 patients ascites (re)occurred during follow up. Refractory ascites was seen in six 
patients. The risk of recurrence of ascites was at the first year 18% (95% CI 4-33) and at 
five years 77% (95% CI 54-100) (figure1B). Ascites which developed during follow up 
could be related to various causes in thirteen patients, namely (gastrointestinal) blood 
loss (n=6) surgical intervention (n=1), septic shock with diverticulitis and liver abscesses 
(n=1) extramedullary haematopoiesis (n=1), protein loosing enteropathy (n=1), periph-
eral stem cell transplantation (n=1), kidney failure (n=1) and shunt occlusion (n=1). In 
ten patients there was no identifiable cause.
Treatment
Twenty-five patients were on diuretic treatment. Reasons to start diuretics were presence 
of ascites (n=20), developing heart failure (n=4) and hypertension (n=1). Only the last 
patients was already on diuretic treatment before the diagnose EPVT was established. 
Two patients underwent porto-systemic shunt surgery for variceal bleeding refractory 
to endoscopic treatment. Three patients received a trans-jugular intra-hepatic porto-
systemic shunt (TIPS) to enable local thrombolyis in the portal vein. Oral anticoagulation 
was used in 14 (50%) patients with ascites. We found that patients with ascites, who 
were not on anticoagulation therapy, had a higher mortality rate (p= 0.07).
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Figure 1. A. Occurrence of ascites in patients with EPVT. B. Recurrence of ascites in patients with EPVT
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survival
Among the total group of 103 patients 20 patients died during follow-up. Causes of 
death were: MPD (n= 5), variceal bleeding (n= 2), infectious diseases (n= 3), cardiovascu-
lar diseases (n= 2) and various other causes (n= 5). In three patients the cause of death 
was unknown.
Survival in the total group of 103 patients was 91% (95% CI 85-97) at five years 
and 80% (95% CI 69-91) at ten years (Figure 2). When we compared patients without 
ascites at diagnosis and with ascites, we found a five years survival of 95% (95% CI 
89-100) versus 83% (95% CI 68-99) and a ten years survival of 87% (95% CI 76-97) 
versus 42% (95% CI 0-83) (Figure 3). In the univariate analysis we found that age (HR 
= 1.1 p = <0.001), MPD (HR = 3.7 p = 0.004), chronic portal vein thrombosis (HR 2.89 
p = 0.03), variceal bleeding (HR 3.64 p 0.01) and ascites at time of diagnosis (HR = 6.6 
p = 0.001) were significant predictors of survival (table 2). In the multivariate analysis, 
after adjustment for age (p<0.01) and sex (p= 0.06), we found that the presence of 
ascites at diagnosis (HR 5.1 p=0.03) was the only independent significant factor which 
predicted survival.
Table 2. Univariate analysis of variables associated with a poor survival
Variable hr (ci 95%) P value
Age (years) 1.08 (1.04- 1.11) <0.001**
Male gender 1.38 (0.53- 3.59) 0.52
Chronic portal vein thrombosis 3.14 (0.91-10.77) 0.04**
Site of thrombosis
- Portal vein
- Portal and splenic veins
- Portal and mesenterial veins
- Portal, splenic and mesenterial veins
1
1.53 (0.33- 7.09)
0.34 (0.04- 2.61)
0.94 (0.30- 2.93)
0.60
0.59
0.30
0.92
Ascites at baseline 6.61 (2.21- 19.73) 0.001**
Ascites at baseline and during follow-up* 4.94 (1.73- 14.14) 0.004**
Ascites during follow-up* 1.78 (0.22- 4.66) 0.59
Presence of MPD 3.68 (1.51- 9.00) 0.005**
Presence of varices1) 1.28 (0.40- 4.11) 0.68
Presence of variceal bleeding1) 3.54 (1.31- 9.56) 0.02**
Splenomegaly1) 1.33 (0.46- 3.83) 0.59
Bilirubin1) 0.03 (1.00- 1.02) 0.03**
Asat1) 0.03 (1.00-1.02) 0.02**
1) variable at baseline
* analysed as a time-dependent factor
** statistical significant
48 Chapter 4
Hoofdstuk 4 figure 3
without ascites
with ascites
Hoofdstuk 4 figure 3
without ascites
with ascites
Figure 3. Kaplan- Meier curve showing the survival of patients with and without ascites and EPVT
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Figure 2. Kaplan- Meier curve showing the overall survival of patients with EPVT
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discussion
In this study we investigated the morbidity and mortality in adult patients with a non-
cirrhotic non-malignant EPVT and ascites. We found that in approximately a quarter of 
the patients ascites was present at the time of diagnosis and that 75% of these patients 
were at risk for a second episode of ascites. This group of patients had a significant 
reduced survival compared to patients without ascites.
According to the literature, ascites in patients with an acute EPVT is correlated with 
mesenterial thrombosis, intestinal ischemia or intestinal infarction [13, 14]. In patients with 
a chronic EPVT ascites is correlated with gastrointestinal hemorrhage, renal insufficiency, 
sepsis and/or surgery [9]. Most of the patients with ascites in our study were patients with a 
chronic EPVT. However in our patients renal function was normal, there was no significant 
relation between age, gastrointestinal hemorrhage, surgery or infection and the presence 
of ascites. Other causes that could clarify the presence of ascites, such as liver failure or 
low osmotic pressure, appeared also unlikely, because all patients lacked histological, 
biochemical and radiologic evidence of cirrhosis. It is known that the onset of ascites in 
patients with a history of thrombotic disease should heighten the clinical suspicion of mes-
enterial venous thrombosis [13]. However, we found no correlation between the extension 
of the thrombus towards the superior mesenteric vein and the presence of ascites.
Mortality in patients with EPVT is often determined by underlying causes [15]. We 
found however a remarkably high mortality rate in the group of patients with ascites 
at the time of diagnosis, which was not correlated with the underlying MPD or other 
etiological factors. Patients with EPVT and an underlying prothrombotic state, who did 
not use oral anticoagulation, had a significantly higher incidence rate of splanchnic 
venous obstruction compared to patients who did use oral anticoagulation[16]. We 
found that in patients with ascites, who were not using oral anticoagulation survival 
was decreased compared to those who did use oral anticoagulation. This underlines the 
need of anticoagulation in EPVT even if esophageal varices are present[16-19].
Our study suffers from the following limitations. Firstly, not all the patients did have 
a liver biopsy, therefore we looked in all other possible ways to exclude cirrhosis. Sec-
ondly, decisions about performing a radiological imaging and starting a specific treat-
ment were made by the treating physician. This led to the fact that not all patients did 
have a systemic radiological imaging during follow up and that the time between the 
radiological imaging differed among the patients. Ascites could have occurred in some 
patients and remained unidentified. There were however clearly no significant signs or 
symptoms suggesting the presence of ascites, according to the medical charts.
In conclusion, in our series of patients with non-cirrhotic non- malignant EPVT, ascites 
is present in about one quarter of the patients. Ascites at the time of EPVT diagnosis is 
independently related to a high mortality rate.
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AbsTrAcT
background: In patients with non- cirrhotic extrahepatic portal vein thrombosis (EPVT) 
anticoagulation therapy should be considered when thrombosis is of recent onset or 
when a prothrombotic state is present. However, data on this topic are scarce. The aim of 
this study was to assess the effect of anticoagulation therapy on gastrointestinal bleed-
ing and recurrent thrombotic events in patient with non- cirrhotic EVPT.
methods: All consecutive patients with non- cirrhotic EPVT, seen at our hospital from 
1985 to 2009 were enrolled in this study. Data were collected by systemic chart review.
results: Hundred-twenty patients (36% male; median age 44 years (range 16-87)) were 
followed after the diagnosis EPVT was made (median follow up 5.5 years, range 0.1-
32.5). Forty patients had recent EPVT, 71 patients had chronic EPVT and in nine cases 
the onset was unknown. Sixty-six patients were treated with anticoagulation therapy. In 
thirty-seven patients 83 bleeding events occurred (variceal bleeding n= 52 and gastro-
intestinal non variceal bleeding n=31). Re-bleeding risk was 19% at one year, 46% at five 
years and 49% at ten years. Gastrointestinal bleeding at presentation (HR 2.1 p=<0.01), 
ascites (HR 2.0 p=0.01) and use of anticoagulation therapy (HR 2.0 p=<0.01) were signifi-
cant predictors of (re)bleeding. Anticoagulation therapy had no effect on the severity of 
gastro-intestinal bleeding. Two out of four patients with fatal gastrointestinal bleeding 
were using anticoagulants.
Twenty-two new thrombotic events occurred in nineteen patients (venous n=15 
arterial n=7). Overall thrombotic risk was 4% at one year, 8% at five year and 27% at 
ten years. Seventy-four percent of all new thrombotic events occurred in patients with 
a prothrombotic disorder. Anticoagulation therapy tended to lower the risk of a new 
thrombosis (HR0.2 p= 0.1), yet the only significant predictor of a new thrombotic event 
was presence of a prothrombotic disorder (HR 3.1 p= 0.03). New thrombotic events were 
significantly associated with poor survival (HR 3.1 p=0.02). Bleeding (HR 1.6 p=0.2) and 
anticoagulant treatment (HR 0.5 p=0.2) had no significant effect on survival.
conclusion: In EPVT patients new thrombotic events were mainly observed in patients 
with prothrombotic disorders. Anticoagulation therapy tended to prevent new throm-
bosis but also significantly increased the risk of gastrointestinal (re)bleeding. This find-
ing suggest that anticoagulation therapy should be used selectively and with caution in 
EPVT patients.
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inTroducTion
Extrahepatic portal vein thrombosis (EPVT) is an important cause of non-cirrhotic portal 
hypertension. Variceal bleeding is one of the major complications of EPVT. [1-5]. Several 
local risk factors for developing EPVT, including cirrhosis, hepatobiliary malignancies and 
pancreatitis, and systemic risk factors, including myeloproliferative neoplasm and pro-
thrombotic genetic defects, have been identified. [6-15] In patients with recent throm-
bosis or with an underlying prothrombotic disorder, anticoagulation therapy is usually 
considered. [15-21] However, data on the risk and benefit of anticoagulation therapy are 
limited. Benefit of treatment was reported by two cohort studies. One of these studies 
addressed anticoagulation therapy in patients with recent EPVT only. [16, 22].
The aim of this retrospective study was to assess the effect of anticoagulation therapy 
on gastro-intestinal (re-) bleeding and thrombotic events during a long-term follow up 
in patients with EVPT.
PATienTs And meThods
design of the study
Patients were identified by means of a search in the computerized patient registration 
system of our clinic. All adult patients identified between January 1985 and November 
2008 were enrolled if EPVT was documented and cancer, cirrhosis, liver transplantation 
or combined Budd-Chiari syndrome were absent. For all patients a standardized clinical 
record form for detailed clinical data was completed with data obtained from the medi-
cal charts.
From a total of 241 patients with EPVT 120 patients were included in this study. Pa-
tients were excluded for the following reasons: 63 patients had cirrhosis, 49 had malig-
nancies, seven had developed EPVT after liver transplantation and two had Budd-Chiari 
syndrome.
Follow-up started at the time of diagnosis, defined as the date of the first radiologi-
cal imaging documenting EPVT, and was continued to either December 2009 or death, 
whichever came first. Patients lost to follow-up were censored at the last visit.
diagnostic assessment
Diagnostic criteria for EPVT were partial or complete obstruction of the extrahepatic 
portal vein, as documented by radiological imaging, such as Doppler ultrasonography, 
computed tomography, magnetic resonance imaging, and venography. Risk factors for 
the development of EPVT were divided in inherited and acquired risk factors. Inherited 
risk factors were: factor V Leiden mutation, prothrombin gene mutation, protein C defi-
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ciency, protein S deficiency, and antithrombin deficiency. Inherited deficiencies of the 
latter three proteins were diagnosed if patients were known with this deficiency prior 
to EPVT or low concentration of these proteins was confirmed at least six weeks after 
the onset of EPVT or in case anticoagulation therapy was given at least six weeks after 
discontinuation, all in the absence of hepatic dysfunction. Acquired risk factors were: 
myeloproliferative neoplasm (MPN), paroxysmal nocturnal hemoglobinuria, antiphos-
pholipid antibody syndrome, abdominal surgery, infection, inflammatory bowel disease 
(IBD), use of oral contraceptives or trauma. Abdominal surgery, trauma or abdominal 
infections were regarded as underlying cause if these events had occurred within three 
months prior to the development of EPVT. EPVT was defined recent in the absence of a 
portal cavernoma and gastrointestinal varices. All other cases were classified as chronic 
EPVT. Gastroesophageal varices were graded as [23]: grade I, varices flattened by insuffla-
tion; grade 2, varices not flattened by insufflation; grade 3, confluence of varices not flat-
tened by insufflation; grade 4, grade 3 with red marks. Anticoagulation therapy included 
treatment with vitamin K antagonists, therapeutic use of low molecule weight heparin 
or heparin. To compare the severity of bleeding between patients with and without 
anticoagulation therapy, we assessed the number of bleeding events per patient, the 
amount of units transfused red blood cells, the number of Intensive Care Unit admissions 
and hemoglobin level at admission for each bleeding episode in both groups.
sTATisTics
Kaplan Meier method was used to calculate (re-) bleeding free, thrombotic free and 
overall survival and the log-rank test was used for comparing groups. Predictors of (re-)
bleeding and new thrombosis were estimated as a hazard ratio (HR) and corresponding 
95% confidence interval (CI) using Cox regression analysis adjusted for sex and age. The 
effect of bleeding, thrombotic events and anticoagulants use on survival were estimated 
as time dependent covariates using Cox regression analysis. Due to the small amount of 
thrombotic events univariate Cox regression models, stratified for number of thrombosis, 
were used to determine significant predictors of thrombosis. Since patients could stop 
and restart anticoagulation therapy during the course, we correlated new thrombotic 
and bleeding events to the therapy used at that time. In case of oral anticoagulation use 
a period of three days was added to the stop date and considered as using anticoagula-
tion therapy. Use of anticoagulation therapy was analysed as a time-dependent factor. 
Sensitivity analysis was performed for subgroups. A p-value of < 0.05 was considered 
statistically significant. Data were expressed as median with the accompanying range and 
Interquartile range (IQR), where appropriate. All statistical analysis were performed with 
the Statistical Package for Social Sciences for Windows, version 16.0 (SPSS, Chicago, IL).
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resulTs
A total of 120 patients, 43 men and 77 females with a median age of 44 years (range 16- 
87 years) were enrolled. Baseline characteristics are summarized in Table 1. In approxi-
mately 50% of the patients thrombosis was confined to the portal vein. In the rest of the 
cases thrombosis was more extensive, involving the splenic and- or mesenteric veins. 
Two patients presented with concomitant thrombosis outside the portal venous system: 
deep vein thrombosis of the lower limb and sinus sagittalis thrombosis, respectively. 
EPVT was diagnosed by ultrasound (n= 69), computed tomography (n= 45), venography 
(n= 2), magnetic resonance imaging (n= 3) and per-operative (n=1). Median duration of 
follow up was 5.5 years (range 0.1- 32.5 years; IQR was 2.0- 10.4 years). A prothrombotic 
state was found in 69(58%) patients. Thirty-nine patients had MPN as determined by ei-
ther bone marrow biopsy and/or JAK2 mutation. Gastro-intestinal blood loss at baseline 
was caused by variceal bleeding, in all except of two patients where angiomatosis of the 
stomach and arteriovenous malformation of the rectum were present.
Sixty-six patients - 29/40 cases with recent EPVT, 33/71 cases with chronic EPVT and 
4/9 cases where onset of thrombosis could not be determined - were treated with 
anticoagulation therapy. In 59 patients therapy was instituted immediately after the 
diagnosis EPVT was established. In the seven other cases anticoagulation therapy was 
started during follow up after a median period of 3.4 years (range 1.2– 15.4). Anticoagu-
lation therapy was used during a median period of 1.9 years (range 0 – 15.8 years; IQR 
was 0.7-5.1 years). Forty-two patients still used anticoagulants at the end of follow up. 
Anticoagulants were stopped in 24/66 patients for the following reasons: completed in-
tended time of treatment (n=16), iron deficiency anemia caused by menorrhagia (n=2), 
epistaxis (n=1), presence of varices grade ≥ 2 or variceal bleeding (n=2) or unknown 
(n=3).
From the 120 patients, 16 were treated with both anticoagulation therapy and an 
antiplatelet drug, 13 were on antiplatelet treatment only and 41 were not on anticoagu-
lation nor on antiplatelet treatment. The number of patients on antiplatelet therapy was 
too small to assess effects on bleeding, recurrent thrombosis or survival.
bleeding
A total of 83 bleeding episodes (variceal bleeding n= 52 and other gastro-intestinal 
bleeding n=31) occurred in 37 patients during follow up. Sixteen patients had a single 
episode of bleeding, 11 patients had two episodes and 10 patients had more than three 
episodes of bleeding (range 3-9 events). The median time that the first bleeding oc-
curred was seven months after EPVT diagnosis was established (range 0.1-11.5 years; 
IQR was 0.2- 3.0 years). Overall risk of gastro-intestinal bleeding was 33% (95% CI 24 
- 41) at one year, 43% (95% CI 33-53) at five years and 46% (95% CI 36-56) at ten years 
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(figure 1). The median time that a rebleeding occurred was four months (range 0.01- 8.6 
years; IQR 0.9- 8 months) after the initial bleeding. Overall risk of re-bleeding was 46% 
(95% CI 36- 56) at one year, 63% at five years (95% CI 52-74) and 69% at ten years (95% 
Table 1. Baseline Characteristics
Variable at baseline Patients
n=120
(%)
Sex (m/f ) 43/ 77
Age (yrs)9*
History of thrombosis
Acute/ chronic thrombosis
44 ± 16 (16 - 87)
14/ 118
40/71
12%
Site of thrombosis
- Portal vein
- Portal and splenic veins
- Portal and mesenteric veins
- Portal, splenic and mesenteric veins
64/120
9/120
17/120
30/120
53%
8%
14%
25%
Underlying cause
Inherited thrombophilia
- Protein C deficiency
- Protein S deficiency
- Antithrombin deficiency
- Factor V Leiden
- Prothrombin gene mutation
Acquired disorders
- Myeloproliferative neoplasm
- Infection
- IBD
- Antiphospholipid syndrome
- Surgery
- Splenectomy
- Oral contraceptive use (females)
- Smoking
24/95
4/82
11/83
4/101
6/86
1/71
96/120
39/120
22/120
7/120
6/88
35/120
7/120
28/113
28/94
25%
5%
13%
4%
7%
1%
80%
33%
18%
6%
7%
29%
6%
25%
30%
At diagnosis
Varices
- Varices grade I/II/III/IV
- Gastro-intestinal bleeding
- Ascites
61/94
10/12/16/16
27/98
32/118
65%
28%
27%
Blood hemoglobin (mmol/ L)10* 7.3 ± 1.7 (3.9 – 13.8)
Platelet count (x 10E9/ L)11* 257 ± 194 (31 –1083)
Bilirubin (μmol/L)12*
Aspartate transaminase (U/ L)13*
14 ± 33 (3 – 242)
27 ± 73 ( 3 – 709)
Alanine transaminase (U/ L)14* 28 ± 59 (9 – 508)
Serum albumin (g/ L)15* 38 ± 7.0 (22- 51)
Serum creatinin (μmol/ L)16* 68 ± 55 (35 – 385)
APTT (sec)* 34 ± 21 (3 – 144)
PT (sec)* 15 ± 10 (10 – 66)
PTINR * 1.3 ± 0.8 (1.0 – 4.3)
* median ± sd (range)
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CI 59- 82) (figure 1). Predictors of (re)bleeding in the univariate analysis are shown in 
table 2. In the multivariate analysis we found that gastrointestinal bleeding (HR 2.1 p= 
<0.01), ascites at baseline (HR 2.0 p=0.01) and use of anticoagulation therapy at the 
time of bleeding (HR2.0 p=<0.01) were significant predictors of gastrointestinal (re)
bleeding. There was no significant relation between the severity of the gastro-intestinal 
bleeding and the use of anticoagulants. Patients with anticoagulation therapy (n=66) 
had 58 bleeding episode versus 25 in patients without anticoagulation therapy (n=54). 
Median hemoglobin level at admission was 5.5 mmol/L (range 1.8- 8.7) in patients with 
anticoagulation therapy versus 5.8 (3.0- 8.5) mmol/L in patients without anticoagulation 
therapy. Median transfused packed red blood cells per bleeding episode was four (range 
2- 20) in both groups. In total there were seven admissions to the ICU in the group of 
patients on anticoagulation therapy versus five in the other group.
new thrombotic events
A total of 22 new thrombotic events occurred in 19 patients (venous events n= 15, arterial 
events n=7). Sites of thrombosis were: pulmonary embolism (n=3), superior mesenteric 
vein (n=2), lower limb (n=4), upper limb (n=4), sinus sagittalis (n=1), mesocaval shunt 
(n=2), intestinal ischemia (n=2) and ischemic stroke (n= 4).The median time between 
diagnosis of EPVT and occurrence of a new thrombotic event was 5.7 years (range 0.1 
No of patients at risk:
First bleeding 92 55 38 31 26 21
Rebleeding 28 37 28 18 14 8
Bleeding
Rebleeding
Hoofd-
stuk 5 
figure 1 
Figure 1. Overall risk of (re)bleeding
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– 19.0 years; IQR was 1.8-8.6 years). Overall risk of a new thrombotic event was 3% (95% 
CI 0-7) at one year, 8% (95% CI 3- 14) at five years and 24% (95% CI 13- 36) at ten years 
(figure 2). Seventy-four percent of the new thrombotic events occurred in patients with 
a prothrombotic disorder. Recurrence or extension of thrombosis into the splanchnic 
veins was only seen in patients with a prothrombotic disorder. Sixteen new thrombotic 
events were found in 69 (23%) patients with a prothrombotic disorder versus six events 
in 51(11%) patients without a prothrombotic disorder. Use of anticoagulants tended to 
reduce the occurrence of a new venous thrombotic event (HR 0.2 p= 0.1). Predictors of a 
new thrombotic event are shown in table 2.
survival
Twenty-nine patients died. Median age of death was 64.2 years (range 30.4- 95.3 years). 
Overall survival was 90% (95%CI 84-96) and 70% (95%CI 58-82) at 5 and 10 years, respec-
Table 2. Univariate analysis of variables associated with bleeding and recurrent thrombosis
bleeding Thrombosis survival
Variable hr
(ci 95%)
P
value
hr
(ci 95%)
P
value
hr
(ci 95%)
P
value
Age (years)*** 1.1 (0.9-1.2) 0.5 1.2 (0.9-1.6) 0.20 1.9 (1.5-2.4) < 0.01**
Female gender 0.7 (0.5-1.1) 0.2 0.9 (0.4-2.4) 0.9 0.9 (0.4-2.0) 0.8
Recent portal vein thrombosis
Chronic portal vein thrombosis 1.1 (0.7-1.8) 0.7 1.2 (0.5-3.0) 0.8 1.7(0.7-4.0) 0.2
Site of thrombosis
- Portal vein only
-  Portal, splenic and mesenteric 
veins
Varices
Varices grade ≥ 2 ****
Gastro-intestinal bleeding at baseline
Gastro-intestinal(re) bleeding during 
the follow up*
Ascites
New thrombotic event*
Anticoagulation therapy *
Underlying causes
- Inherited
- Acquired
 § MPD
 § Infection
 § IBD
- Prothrombotic disorder
1
1.7 (1.0-2.9)
1.0 (0.6-1.7)
4.2 (1.0-18.0)
1.7 (1.0-2.7)
2.2 (1.3-3.6)
1.7 (1.1-2.7)
1.0 (0.5-1.7)
0.7 (0.4-1.1)
1.2 (0.8-2.0)
0.6 (0.3-1.3)
-*)
1.1 (0.7-1.7)
0.2
0.04**
0.9
0.02**
0.04**
< 0.01**
0.03**
0.9
0.1
0.4
0.1
0.7
1
1.4 (0.5-3.9)
0.7 (0.3-2.0)
1.1 (0.2-5.7)
1.3 (0.5-3.6)
1.7(0.5-5.5)
0.2 (0.0-1.9)
1.0 (0.3-3.6)
0.9 (0.3-2.8)
1.9 (0.8-4.5)
0.3 (0.8-1.5)
1.0 (0.2-4.4)
3.1(1.0-9.5)
0.2
0.5
0.5
0.9
0.6
0.4
0.1
0.9
0.9
0.2
0.1
0.9
0.03**
1
1.0 (0.4-2.6)
0.9 (0.4-2.3)
1.3 (0.3-6.1)
1.6 (0.7-3.5 )
6.1 (2.2-16.4)
3.1 (1.2-8.0)
0.5 ( 0.2-1.3)
0.3 (0.0- 2.5)
1.4 (0.5-4.0)
2.6 (1.3-5.5)
0.3 (0.1-1.1)
0.8 (0.2-3.5)
3.0(1.2-7.4)
0.8
0.9
0.8
0.8
0.2
<0.01**
0.02**
0.2
0.2
0.6
0.01**
0.04**
0.8
0.01**
* Analysed as a time-dependent factor
** Statistical significant
*** Ten-year increment
****According the Paquet Classification[23]
*)There were not enough bleeding events observed to assess the effect of IBD
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Patients at risk:
120 87 64 52 41 26
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figure
2
Figure 2. Overall risk of new thrombotic event
No of patients at risk:
120 89           67            57             44 32 25 21
Hoofd-
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figure 3
Figure 3. Overall survival
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tively (figure 3). Predictors of survival in the univariate analysis are presented in table 2. 
In the multivariate analysis increased age (HR 1.1 p= < 0.01) and ascites at diagnosis (HR 
4.0 p= <0.01) were the only significant factors associated with increased mortality. In 
the time- dependent covariate analysis we found that a new thrombotic event was sig-
nificantly associated with a poor survival (HR 3.1 p=0.02). Gastrointestinal bleeding (HR 
1.6 p=0.2) and anticoagulants use had both their effect (HR 0.5 p= 0.2) on survival, but 
not statistically significant. Five patients died due to a bleeding: cerebellar hematoma 
(n=1), variceal bleeding (n=2) and other upper gastro-intestinal bleeding (n=2). The lat-
ter two patients were both on anticoagulation therapy. Three patients died due to a new 
thrombotic event (necrotic colon due to massive arterial ischemia, ischemic cerebral 
vascular accident and sinus sagittalis thrombosis. The last two patients were both on 
anticoagulation therapy when the thrombotic events occurred. Other causes of death 
were progressive MPN (n= 6), infection (n=3), other causes (n= 7) and unknown (n= 5)
discussion
In this study we investigated anticoagulation therapy and other factors associated with 
gastrointestinal bleeding, new thrombotic events and survival in patients with non- cir-
rhotic non malignant EPVT. In about twenty percent of the patients with a prothrom-
botic disorder a new thrombotic event occurred, which was significantly associated 
with decreased survival. Anticoagulation therapy showed a tendency to prevent new 
thrombosis, however it significantly increased the risk of gastro-intestinal bleeding.
As is known from previous studies (re)bleeding is mainly determined by size of varices 
and initial presentation of a gastrointestinal bleeding [5, 16, 24]. In addition to these fac-
tors, we found that both extension of thrombosis into the splanchnic veins as ascites at 
baseline were significant factors predicting (re)bleeding. These new findings may help 
to identify patients with a high risk of gastrointestinal bleeding and also may influence 
whether to start anticoagulation therapy. Condat et al. concluded that the benefit-risk 
ratio favours anticoagulation therapy for most patients with EPVT[16]. They made this 
conclusion on two major findings. Firstly, the risk of new thrombotic events was pro-
foundly reduced by anticoagulation therapy. This reduction involved mainly thrombotic 
recurrence or extension within the portal venous system. Secondly, they did not find a 
significant correlation between the risk and severity of gastro-intestinal bleedings and 
the use of anticoagulation therapy. We found that patients with EPVT and a prothrom-
botic disorder had a three-fold increased risk to develop new thrombotic events both 
in and outside the splanchnic veins. Extension of thrombosis into the splanchnic veins 
occurred only in patients with a prothrombotic disorder. These findings suggest that 
anticoagulation therapy is warranted in patients with a prothrombotic disorder. In our 
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study anticoagulation therapy tended to have an overall beneficial effect on decreasing 
new thrombotic events and even somewhat on improving survival. On the other hand 
the use of anticoagulation therapy significantly increased the risk of gastrointestinal 
bleeding. A total of four patients (3%) died due to gastrointestinal bleeding, two were 
on anticoagulation therapy. Three patients (3%) died due to a thrombotic event, of 
which two were on adequate anticoagulation therapy.
With this study we support the current guidelines which state that anticoagulation 
therapy can be considered in patients with EPVT and an underlying prothrombotic dis-
order [19, 25]. However, we also found that anticoagulation therapy is not without risk.
Our study has several limitations. Decisions about anticoagulation treatment and 
performing radiological imaging were made by the treating physician. This led to the 
fact that not all patients did have a systemic radiological imaging during follow up and 
that the time between radiological imaging differed among the patients. Recurrence 
of portal vein thrombosis or extension of thrombosis into the splanchnic veins could 
have occurred in some patients and remained unidentified. Especially in those cases 
where no clinical significant signs or symptoms were present. Patients with an extensive 
thrombosis are more likely to get anticoagulation therapy than patients presenting 
with a gastro-intestinal bleeding. Both factors were carefully taken into account in the 
uni- and multivariate analysis. Furthermore during the long study period new insights 
and diagnostic tests have been developed. This may have led to an underrepresenta-
tion and - treatment of patients with prothrombotic disorders enrolled in the early part 
of the study. In parallel, these patients were initially not on anticoagulation therapy. 
Also patients could stop and restart anticoagulation therapy during their course. We 
therefore analyzed each bleeding or thrombotic event according to the therapy used 
at that time.
In conclusion, in patients with non- cirrhotic EPVT new thrombotic events occur 
primarily in patients with a prothrombotic disorder and are significantly associated with 
decreased survival. Anticoagulation therapy can lead to prevention of new thrombosis, 
but also significantly increases the risk of gastrointestinal bleeding. These findings imply 
that anticoagulation therapy on one hand is warranted in patients with EPVT and an 
underlying prothrombotic disorder, while on the other hand it should be given with 
caution to those with high risk of bleeding.
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AbsTrAcT
introduction: Transcatheter local thrombolytic therapy in patients with acute, extended 
splanchnic venous thrombosis is controversial. Here we present our single-center expe-
rience with transcatheter thrombolytic therapy in these patients.
methods: All consecutive patients (n=12) with acute, extended splanchnic venous 
thrombosis who underwent transcatheter thrombolytic therapy in our hospital, were 
included in this study.
results: Thrombolytic therapy was successful for three thrombotic events and partially 
successful for four thrombotic events. Two patients developed minor procedure related 
bleeding (17%). Six patients (50%) developed major procedure related bleeding, with a 
fatal outcome in two.
conclusions: Transcatheter thrombolytic therapy in patients with acute, extended 
splanchnic vein thrombosis is found to be associated with a high rate of procedure 
related bleeding. Therefore, thrombolysis should be reserved for patients in whom the 
venous flow cannot be restored by using conventional anticoagulant therapy or stent 
placement across the thrombosed vessel segment.
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inTroducTion
Splanchnic venous thrombosis (SVT) comprises thrombosis of the hepatic veins and 
the portal venous system. It includes the Budd-Chiari syndrome (BCS), characterized 
by hepatic outflow obstruction (1) and portal vein thrombosis (PVT) (2). SVT is often 
related to prothrombotic disorders (3, 4) or caused by underlying haematological 
diseases that predispose to hypercoagulability, such as myeloproliferative diseases 
and paroxysmal nocturnal haemoglobinuria (5, 6). One of the treatment options in SVT 
patients is locally delivered transcatheter thrombolytic therapy, which is mainly used in 
patients with acute, combined thrombosis of both portal and hepatic veins. Several case 
studies or small case series describe successful thrombolytic therapy in SVT patients 
with a low incidence of bleeding complications (7-14). However, these reports should 
be interpreted with caution in view of a potential publication bias of successful cases. 
Only two larger studies have been performed in which success and complication rates 
vary widely (15, 16). Therefore, it is difficult to properly assess the risk/benefit ratio and 
thrombolytic therapy remains controversial. Here we present our single-center experi-
ence with thrombolytic therapy in a series of consecutive patients with SVT.
mATeriAl And meThods
All SVT patients who underwent transcatheter thrombolytic therapy in our hospital, 
between January 1996 and December 2007, were included in this study. Clinical records 
of all patients were reviewed and demographics, etiology, clinical presentation, duration 
of symptoms, details of thrombolytic therapy, outcome, complications and follow-up 
were reported in a standardized way. The diagnosis of SVT was established by computed 
tomography, transcatheter portography, magnetic resonance imaging or Doppler Ul-
trasound. The obstruction was graded partially when there was a significant remaining 
patent vein lumen or complete. The Child-Pugh score was used as an indication of liver 
function prior to thrombolytic therapy in patients with cirrhosis and BCS. Patients were 
followed from initiation of thrombolysis until death, study closure (December 31, 2007), 
or, in case of loss to follow up, the last date of visit. Survival rates were calculated by 
means of the Kaplan-Meier method.
Patients were considered for thrombolysis if they met the following criteria. First, only 
patients with an acute thrombosis (duration of symptoms ≤ 14 days) were considered 
for thrombolytic therapy. Second, thrombolytic therapy was only used in patients with 
thrombosis in two or more vessel systems in the splanchnic area, e.g. thrombosis of the 
hepatic veins combined with PVT. Third, in most patients thrombolysis was considered 
after standard anticoagulant therapy had proven insufficient, i.e. in patients exhibiting 
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a progressive thrombosis or a clinical deterioration despite anticoagulation. Informed 
consent was obtained from each patient after informing them on the possible risks and 
benefits of the treatment.
To facilitate creation of the transhepatic tract from the liver vein (inferior caval vein 
in BCS) to the portal vein during transjugular intrahepatic portosystemic shunt (TIPS) 
placement, a marker catheter was introduced in the portal vein by the direct percutane-
ous transhepatic route and by using ultrasound guidance. The decision to deliver trom-
bolytic therapy through a percutaneously inserted transhepatic catheter, or through 
a catheter placed through a pre-existing or specially created TIPS, was not a constant 
but rather evolved over time – influenced also by literature suggesting the benefit of 
additional TIPS for thrombolysis (17-19). Thrombolysis was considered successful when 
vessel patency and blood flow were restored, as observed during venography, and 
considered partially successful when flow was restored in some, but not all, thrombosed 
veins. Thrombolysis was considered unsuccessful when no lysis was obtained in any of 
the occluded vessels. Thrombolytic therapy was discontinued in case of resolution of the 
thrombus or in case of severe bleeding.
All patients were initially treated by APTT-controlled (APTT ratio 2.2-2.9, reflecting an 
anti Xa activity of 0.3-0.7 U/ml) infusion of unfractionated heparin (UFH) or a therapeutic 
dose of low molecular weight heparin (LMWH, dalteparin, 200 U/kg BW s.c.). Recom-
binant tissue type plasminogen activator (Actilyse®, Boehringer-Ingelheim, Germany), 
rtPA, was used as thrombolytic agent and was delivered by means of a locally placed 
catheter. Patients were treated by continuous infusion of 2-4 mg/hr rtPA, in some cases 
preceded by a 4-10 mg bolus injection. In one patient urokinase was administered. Dur-
ing thrombolysis all patients were admitted to an intensive care unit for hemodynamic 
monitoring. Low dose UFH was continued during thrombolytic treatment (10,000 IU/ 
24 hours). After thrombolytic treatment was stopped, UFH was again administered in a 
therapeutic dosage and was discontinued once the patient was adequately anticoagu-
lated with vitamin K antagonists. After discharge from hospital, patients were followed 
at the outpatient department of our hospital.
resulTs
Patient characteristics
Twelve patients (58% male) with a mean age of 32 years (range 26-53) underwent 
thrombolytic therapy and were included in this study. Six patients had BCS with ad-
ditional thrombosis in the portal system. The majority of patients had an underlying 
pro-thrombotic haematological disorder. Patient characteristics, including etiology and 
indication for thrombolytic therapy, are presented in table 1.
Thrombolytic therapy in SVT patients 71
details of thrombolytic therapy and outcome
Twelve patients were treated with thrombolytic therapy for thirteen thrombotic events. 
One patient (pt. 12) was treated twice, because of renewed thrombosis five days after 
initial successful thrombolysis despite heparin therapy. Route of delivery of the throm-
bolytic agent was percutaneous transhepatic (n=4), transjugular transhepatic (n=6) or 
other (n=3). The total percutaneous transhepatic catheters amounted to eight, in which 
they were either used as a marker catheter to facilitate TIPS placement, or as an indwell-
ing catheter trough which the thrombolytic agent was administered. TIPS insertion/
revision was performed in six patients. Thrombolysis was successful for three thrombotic 
Table 1. Characteristics of 12 patients with splanchnic vein thrombosis (SVT) treated with thrombolysis
Pt. sex Age etiology indication duration 
of symp-
toms
child-
Pugh 
class
budd-chiari syndrome
1. M 26 Factor V Leiden 
(heterozygous)
Progression of thrombosis despite 
heparin
9 days A
2. F 30 Factor V Leiden 
(homozygous), OCC
Progression of thrombosis despite 
heparin
14 days A
3. M 33 Myeloproliferative disease Clinical deterioration despite 
anticoagulation
7 days C
4. M 30 Paroxysmal nocturnal 
hemoglobinuria
Progression of thrombosis despite 
anticoagulation
7 days B/C
5. F 26 Antiphospholipid antibodies, 
OCC
Progression of thrombosis despite 
heparin
7 days B
6. M 38 Myeloproliferative disease Thrombotic complication during TIPS 
creation
C
Portal vein thrombosis
7. F 34 Lymphoma, splenectomy Extensive post-splenectomy thrombosis 7 days -
8. F 25 Lymphangiomatosis, OCC Extensive PV and MV thrombosis 14 days -
9. F 27 OCC, hyperhomocysteinemia Progression of thrombosis despite 
heparin
12 days -
10. M 27 Hemolytic anemia, 
splenectomy
Progression of thrombosis despite 
heparin
9 days -
cirrhotic patients
11. M 53 Alcoholic liver cirrhosis Extensive thrombosis and thrombotic 
complication during TIPS creation
8 days C
12. M 37 Auto-immune liver cirrhosis, 
ulcerative colitis
TIPS dysfunction and extensive 
thrombosis with a thrombotic 
complication during TIPS revision 
and renewed thrombosis despite 
anticoagulation
6 days B
OCC: oral contraceptives; PV: portal vein ; MV : mesenteric vein ; TIPS : transjugular intrahepatic 
portosystemic shunt.
Child-Pugh score was obtained for patients with BCS and liver cirrhosis.
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events in two patients (pt. 7 and 12). Therapy was partially successful in four patients (pt. 
2, 5, 6 and 8). Details of thrombolytic therapy are presented in table 2. Five out of six pro-
cedures which were combined with a TIPS insertion/revision were (partially) successful.
complications
Two patients developed minor bleeding, not requiring transfusion, after cessation of 
thrombolytic therapy (pt 2 and 7). Six patients developed major bleeding necessitating 
discontinuation of thrombolytic treatment. In two of these patients, thrombolysis had 
been partially successful at that time (pt. 5 and 8).
One patient died directly related to bleeding (pt. 3). This BCS patient had additional 
PVT and MVT and developed a fatal massive sub-capsular liver haemorrhage resulting 
in hypovolemic shock. Patient 11 died two weeks after thrombolytic therapy, which was 
complicated by bacterial peritonitis and renal failure after massive abdominal bleeding. 
The patient eventually died from multiple organ failure. The death of this patient was 
considered to be partly caused by procedure related bleeding.
Four patients developed major, but nonfatal, bleeding, including retroperitoneal 
bleeding (pt 4), intraperitoneal bleeding (pt 5), massive intra-abdominal bleeding (pt 8) 
and a subcapsular liver haematoma (pt 9) (table 2).
clinical parameters related to outcome
Laboratory evaluation showed a marked decrease of fibrinogen in patient 2, 3, and 11 
(pre-treatment values of 3.6 g/l, 2.2 g/l, and 2.5 g/l, respectively [normal 1.5-3.6 g/l]) to a 
nadir of 0.6 g/l, 0.3 g/l and 0.7 g/l, respectively, during thrombolytic treatment. Patient 5 
already had a pre-treatment fibrinogen of 0.7 g/l and remained < 1.0 g/l during throm-
bolysis. These four patients all developed bleeding complications (of which three major 
bleeding). The two patients with a fatal outcome showed the lowest fibrinogen levels of 
all patients (0.3 g/l and 0.4 g/l) during thrombolytic therapy. None of the four patients 
without bleeding complications had fibrinogen levels <1.0 g/l (table 3).
The Child-Pugh score was obtained for six patients with BCS and two patients with 
liver cirrhosis. Six patients had a Child-Pugh score > 7 and were considered to have liver 
dysfunction. Four of these patients developed major bleeding complications, of which 
two were fatal. The two patients with a fatal outcome exhibited the highest Child-Pugh 
scores. Bleeding complications were also observed in four of six patients with a normal 
liver function, of which two were major (table 3).
Follow-up
The mean time of follow-up was 3.7 years (range 3 days – 10.6 years). Survival according 
to Kaplan-Meier analysis at 1, 3 and 5 years was 67% (95% CI, 40%-93%). One patient 
was lost to follow-up. Patient 1 and 4 died 5.6 and 2.9 months after thrombolysis, respec-
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tively, due to multiple complications of combined BCS and PVT, which were not related 
to thrombolysis. Patient 7 died 7.5 years after thrombolysis from lymphoma.
discussion
Both systemic and local administration of thrombolytics have been described in the 
treatment of SVT, but the latter is preferred (15, 16, 20). Despite several successful single-
case reports and two larger case-series, thrombolytic treatment remains controversial 
(7-16). In our study, one of the largest series on thrombolysis in SVT patients, we report 
slightly lower success rates accompanied by a previously unreported high rate of proce-
dure related bleeding.
When thrombolytic therapy is indicated, TIPS placement, creating a patent portal ve-
nous outflow tract to the systemic venous circulation, followed by local administration of 
thrombolytic agents in the portal vein appears an effective approach. This is supported 
by previous reports (17-19). In three out of six TIPS procedures, major bleeding occurred 
and one patients eventually died, however, it is difficult to determine whether this is 
related to the TIPS procedure itself. The invasive procedure necessary for using local 
thrombolysis has a great overlap with the TIPS procedure. Therefore, it seems prudent to 
simultaneously create a TIPS when performing thrombolysis, as a patent TIPS has been 
shown to be beneficial in terms of clinical improvement and survival in SVT patients 
(21-23).
The relation between fibrinogen levels and bleeding risk suggests that, for safety 
reasons, it is prudent to monitor fibrinogen levels during thrombolysis and fibrinogen 
should be supplemented if levels fall <1.0 g/l. Our results indicate that liver dysfunc-
tion might be a risk factor for procedure related bleeding, implying that thrombolysis 
should be cautiously used in these patients. The association between the percutaneous 
transhepatic approach and bleeding concurs with previous reports, where also the 
transjugular approach was preferred (16, 24, 25).
Table 3. Fibrinogen levels and liver function during thrombolytic therapy in relation to bleeding 
complications
number of 
patients
major bleeding
n (%)
minor bleeding
n (%)
no complications
n (%)
Fibrinogen < 1.0 g/l 4 3a (75%) 1 (25%) 0 (0%)
Fibrinogen > 1.0 g/l 8 3 (38%) 1 (13%) 4 (50%)
Liver dysfunction 6 4a (67%) 0 (0%) 2 (33%)
No liver dysfunction 6 2 (33%) 2 (33%) 2 (33%)
aOutcome was fatal in two patients.
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A limitation of our study is that it is a single-center, retrospective study with a limited 
number of patients. Patients are heterogeneous in terms of etiology, clinical presenta-
tion, extent of thrombosis, baseline health status and details of thrombolytic therapy. 
Our study population is highly selected from a large number of cases referred to our spe-
cialized tertiary care center and most of the patients had a deteriorating clinical course 
before thrombolytic therapy was initiated. The strength of our study is that it includes all 
patients that have been treated avoiding publication bias of successful cases.
In conclusion, in a series of consecutive patients receiving locally delivered throm-
bolysis for acute, extended SVT we found a previously unreported high rate of bleed-
ing complications. These patients generally have a poor prognosis (26) and it is up to 
the treating physician to determine whether the potential benefits of thrombolysis 
outweigh the apparent risks associated with the procedure. Based on our findings, and 
previous reports in the literature, we have come to the following preferred approach in 
patients with acute, extended SVT. Start with conventional anticoagulant therapy and in 
case of insufficient results proceed to TIPS placement. If venous flow cannot be restored 
by either of these treatment modalities, local thrombolytic therapy, administered via 
transjugular approach, can be considered.
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AbsTrAcT
background: Extrahepatic portal vein thrombosis (EPVT) has been associated with 
the appearance of biliary changes. Although biliary abnormalities, or portal biliopathy, 
can be detected in almost all patients with chronic EPVT, only a few patients become 
symptomatic. The aim of this study was to assess the incidence of symptomatic portal 
biliopathy in a large cohort of patients with a non- cirrhotic non- malignant EPVT and 
describe its clinical features and outcome.
methods: From our cohort of consecutive patients with non-cirrhotic non- malignant 
EPVT, seen at our hospital from 1985 to 2010, we assessed all patients with overt clinical 
signs of cholestasis. These patients were reviewed to study the presentation, manage-
ment and outcome of symptomatic portal biliopathy.
results: From a total of 122 patients (37% males) with a median follow up of 5.5 years 
(range 0-59 years), 18 patients (15%) had signs of cholestasis. From these 18 patients, 10 
patients were excluded because biliary abnormalities were absent. Eight (7%) patients 
met our criteria for symptomatic portal biliopathy. Median time between diagnosis of 
EPVT and the occurrence of symptomatic portal biliopathy was 3.5 years (range 0-38 
years). ERCP revealed intra- and extrahepatic strictures with dominant stenoses in the 
extrahepatic bile duct. A total of 30 ERCP-procedures were performed in seven patients. 
ERCP was effective in four out of the other six patients. One (3%) ERCP-related complica-
tion (cholangitis) was reported.
conclusion: In patients with non- cirrhotic EPVT symptomatic portal biliopathy is an 
infrequent problem. Both intra- and extrahepatic bile duct strictures are present. ERCP 
as first line treatment appears to be effective and safe in patients with symptomatic 
portal biliopathy.
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inTroducTion
In the absence of liver cirrhosis, thrombotic occlusion of the extrahepatic portal vein is 
the most common cause of portal hypertension (1). Especially in developing countries, 
extrahepatic portal vein thrombosis (EPVT) is frequently diagnosed in patients present-
ing with upper gastrointestinal bleeding or splenomegaly (2-3). In Europe, non-cirrhotic 
EPVT is less common but due to the widespread use of imaging techniques it is increas-
ingly being recognized, specifically in asymptomatic patients (4). Although a cause for 
thrombosis is not always found, well-known risk factors for EPVT are local inflammation, 
such as pancreatitis, and systemic prothrombotic conditions such as myeloproliferative 
neoplasms and prothrombin disorders (5-6). Complete occlusion of the main portal vein 
inevitably leads to increased portal pressure causing portal hypertension (7). Develop-
ment of gastroesophageal varices as a result of portal hypertension is considered the 
most important complication of EPVT. However, the severity of portal hypertension and 
its complications differs greatly between individual patients. In part, this is due to the 
compensatory effects of collateral vessels that develop in response to the portal vein 
obstruction (8). Generally, a network of these collaterals develops, often referred to as a 
portal cavernoma.
A less recognized complication associated with EPVT is portal biliopathy. This term 
denotes morphologic abnormalities of the biliary tree, most commonly the extrahepatic 
bile ducts, that are related to the presence of periportal and pericholedochal collaterals 
(9). Possible abnormalities are irregular, albeit smooth, strictures or segmental dilata-
tions. The cause of these changes has not been fully clarified but it has been postulated 
that direct compression of the bile ducts by the cavernoma plays an important role. (10) 
Although structural changes have been described in large percentage of patients with 
EPVT (11-12), the number of patients with symptomatic portal biliopathy is unknown. 
Few studies have described the prevalence and features of this group of patients. In this 
long-term follow-up study, we have evaluated the incidence and clinical outcome of 
patients with non-cirrhotic EPVT and symptomatic portal biliopathy.
PATienTs And meThods
The study cohort consisted of patients with non- cirrhotic non- malignant EPVT that 
were seen at our tertiary referral center from January 1985 until April 2010. Patients 
with Budd-Chiari syndrome, patients with overt carcinoma or patients who had un-
derwent a liver transplantation were excluded from the study. The diagnosis of EPVT 
was established by radiological imaging, such as Doppler ultrasonography, computed 
tomography, magnetic resonance imaging, and venography. Cirrhosis was excluded by 
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liver biopsy and/or a combination of radiological imaging and biochemical tests. EPVT 
was defined as chronic when hepatopetal collaterals or gastrointestinal varices were 
present. When these features were absent, the onset of EPVT was considered recent.
From this cohort, we assessed all patients with overt signs of cholestasis, defined as 
cholangitis (fever >38°C with dilated bile ducts), jaundice (bilirubin >35 umol/l) and/or 
choledocholithiasis, either at the time EPVT was diagnosed or during follow-up. Portal 
biliopathy was diagnosed when cholangiographic abnormalities were documented with 
magnetic resonance cholangiography (MRCP) or endoscopic retrograde cholangiopan-
creatography (ERCP). These cholangiographic abnormalities included strictures, caliber 
irregularities, segmental dilatations, collaterals causing extra-luminal bile duct impres-
sion, and choledocholithiasis located above a stenosis and not associated with gallblad-
der stones (13-14). A patient was considered as having symptomatic portal biliopathy 
when one or more of these cholangiographic abnormalities was present together with 
signs of cholestasis (i.e. cholangitis, jaundice or choledocholithiasis). As a differential 
diagnosis between cholestasis caused by vascular bile duct injury and cholestasis result-
ing from other causes can be difficult, patients were divided into two groups based on 
whether or not additional causes of cholestasis were present. For each patient clinical 
data, treatment and outcome were extensively reviewed using standardized data forms.
resulTs
A total of 122 patients with EPVT were enrolled in the study cohort. Median age at 
diagnosis was 44 years (range 16- 87 years) and 45 cases (37%) were males. A recent 
thrombosis was diagnosed in 39 patients (32%), signs of chronic EPVT were present in 
74 patients (61%) and in 9 patients (7%) the onset of the EPVT was not known. Median 
follow-up of the total cohort after diagnosis was 5.5 years (range 0.1-59 years). Eighteen 
patients (15%) had signs of cholestasis, either at diagnosis of EPVT or at some time 
during follow-up. Ten of these patients were subsequently excluded from the study as 
cholangiography did not show any abnormalities (n=9) or because the biliary tree was 
not visualized (n=1). (Figure 1) Underlying causes of cholestasis in these ten excluded 
patients were chronic pancreatitis (n=3), cholecystectomy-related complications (n=2 
), liver abscess (n=2), drug-induced liver disease (n=2), and choledocholithiasis (n=1). 
Eight patients (7%) met our criteria for symptomatic portal biliopathy. Portal biliopathy 
was diagnosed on MRCP in one case whereas the other seven cases underwent ERCP. 
Baseline characteristics of the patients with symptomatic portal biliopathy are shown 
in Table 1. Four patients were diagnosed with symptomatic portal biliopathy without 
any additional cause of cholestasis. Median time between diagnosis of EPVT and the oc-
currence of symptomatic portal biliopathy was 3.5 years (range 0-38 years). Presenting 
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symptoms were increased cholestatic pattern of liver function tests (n=8), jaundice (n=5), 
right upper abdominal pain (n=3) and fever (n=1). A total of thirty ERCP-procedures 
were performed in seven patients with symptomatic portal biliopathy with a median 
of five ERCP-procedures per patient (range 1-8). In one patient ERCP was not performed 
as the symptoms of cholestasis were also related to a liver abscess, which was treated 
with radiological drainage (case 7). ERCP revealed a dominant stenosis in the proximal 
or middle part of the common bile duct (CBD) in all four patients that did not have 
an additional cholestasis-related factors.(figure 2) In the four patients with symptom-
atic portal biliopathy in whom an additional cholestasis-related factor was present the 
dominant stenosis was mostly located in the distal part of the CBD. (Table 1) Histology or 
cytology of the stenosis was performed in two patients and did not show any dysplastic 
cells. Seven patients with symptomatic portal biliopathy underwent a therapeutic ERCP, 
whereby cannulation of the CBD failed in one patient. The following therapeutic ERCP 
interventions were performed: sphincterotomy (n=3), balloon dilatation (n=9), place-
ment of an endoprosthesis (plastic n=11 or metal n=1), placement of a nasobiliary drain 
(n=2) and a balloon trawl to extract debris and stones (n=2). Ursodeoxycholic acid was 
prescribed in three out of eight patients. In these three patients bile duct stones were 
present and they were treated with endoscopic extraction of the stones and ursodeoxy-
cholic acid, which was effective in all cases. No bleedings from the biliary tree occurred 
during stone extraction.
Total patients with non cirrhotic non 
malignant EPVT
N = 122
Patients with cholestasis related 
symptoms
N = 18
Patients with cholestasis related symtoms 
in the absence of portal biliopathy
N = 10
Patients with single diagnosis 
symptomatic portal biliopathy
N = 4
Patients with symptomatic portal 
biliopathy
N = 4
Hoofstuk 7 figure 1
Figure 1. Diagram of patient selection
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Of the six patients in whom cannulation of the CBD was achieved, ERCP was success-
ful in four cases. In these patients no episodes of cholangitis did occur and bilirubin 
remained normal. The two other patients continued to experience recurrent episodes 
of cholangitis despite repeated ERCP-procedures. One of these patients (case 5) sub-
sequently underwent a biliary-digestive anastomosis. However, during the operation 
a hepaticojejunostomy could not be performed and the patient died two days later 
due to liver necrosis caused by an obstruction of the hepatic artery. The other patient 
(case 3) with a history of kidney transplantation could not be operated and eventually 
died resulting from ongoing cholangitis. The median symptom-free survival of the six 
patients successfully treated by ERCP was 7.5 years (0.4-14 years). Of the total of 30 
ERCP-procedures, one (3%) ERCP-related complication (cholangitis) occurred.
discussion
In this study we have evaluated the incidence and outcome of symptomatic portal bili-
opathy in a large cohort of consecutive patients with non-cirrhotic non-malignant EPVT. 
We found that symptomatic portal biliopathy was present in 7% of the cases. Therapeu-
tic ERCP was the treatment modality of choice in almost all these patients. Although 
repeated ERCP procedures were often needed, it appeared to be safe and effective for 
most of our patients.
Hoofdstuk 7 figure 2
Figure 2. ERCP of case 1 showing a proximal CBD stenosis with dilatation of the biliary tree
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In patients with portal hypertension due to EPVT, collateral vessels will develop within 
the hepatoduodenal ligament and in the vascular plexus of the bile ducts. Dilatation of 
veins in the paracholedochal plexus and the epicholedochal venous plexus can subse-
quently cause bile duct compression. The resulting bile duct irregularities, described as 
portal biliopathy, are shown to be present in nearly all patients with chronic EPVT. (10-
11,13) However, symptoms related to portal biliopathy are rarely seen and data on this 
topic are scarce. The incidence of symptomatic portal biliopathy differs in literature from 
5-33%, due to marked differences between small selected study populations. (10, 13-17) 
It has been suggested that the incidence of symptomatic portal biliopathy is higher in 
developing countries compared to Western countries.(18) However, our incidence of 7% 
concurs with a large Indian cohort study which reported an incidence of symptomatic 
portal biliopathy in 4% of the patients with EPVT.(19) Symptomatic portal biliopathy 
thus remains a rare complication in patients with EPVT and screening for this disorder 
does not seem useful. Still, due to a better control of gastrointestinal bleeding and recur-
rent thrombotic events, the outcome of chronic EPVT has improved over the last ten 
years.(11) As portal biliopathy is mostly seen in patients with presumably long-standing 
EPVT, an improved prognosis can potentially lead to an increase in late EPVT-related 
complications, such as portal biliopathy. (10, 13)
Choledocholithiasis associated with portal biliopathy has previously been character-
ized by three specific features: 1) bile duct stones are located proximal of the stenosis, 2) 
they are not associated with gallbladder stones and 3) they are of the pigment type. (10, 
20) Three patients in our cohort had choledocholithiasis, in the absence of gallbladder 
stones, and the bile duct stones were located in the dilated portion of the bile duct, 
proximal of the stenosis. All three patients were successfully treated with ERCP. As ursode-
oxycholic acid is effective in controlling cholestasis-related symptoms and intrahepatic 
stones (21), this was prescribed in these patients with no recurrence of biliary symptoms. 
In concordance with Bhatia et al, who performed ERCP-procedures with sfincterotomy 
for portal biliopathy-induced choledocholithiasis, we also found a low ERCP-related 
complication rate and no bleedings.(20) Our results support the treatment algorithm 
proposed by Chandra et al., where endoscopic treatment should be considered as the 
first line treatment for stone extraction or dilatation with or without stent insertion. (22) 
In those cases where biliary drainage by endoscopic and radiological approach is not 
successful portal biliopathy remains a challenging problem (20, 23). For the second-line 
treatment of symptomatic portal biliopathy, a portosystemic shunt, if feasible, should be 
considered. It is, however, questionable if this treatment is successful for patients with 
a dominant biliary stenosis unrelated to the present portal biliopathy. Another option 
is a biliary-intestinal bypass, however this type of surgery is accompanied with a high 
risk of morbidity in the setting of portal hypertension (24-25), as shown in our patient. 
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Therefore, this surgical intervention should only be considered in those cases where 
other treatment modalities have failed. (10, 22)
In conclusion, in patients with non-cirrhotic non-malignant EPVT, symptomatic portal 
biliopathy is an uncommon complication of portal hypertension, occurring in less than 
10% of the cases. When present, ERCP appeared to be an effective and safe first-line 
treatment modality. Larger series of patients will be required to determine the true 
complication rate of ERCP-procedures for portal biliopathy.
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summAry And discussion
This thesis focused on patients with non- cirrhotic non- malignant extrahepatic portal 
vein thrombosis (EPVT). EPVT is defined as obstruction of the extrahepatic portal vein 
with or without involvement of the intrahepatic portal veins and does not include iso-
lated thrombosis of splenic or superior mesenteric vein. Clinical presentation depends 
on the onset of the thrombosis. The typical presentation of a recent thrombosis is with 
abdominal pain. Fever and ascites, usually in small quantities and of transient character, 
may also be present. Chronic EPVT most frequently presents with problems related to 
portal hypertension, including gastrointestinal bleeding, splenomegaly and ascites. For 
most patients, in whom EPVT is suspected, diagnosis can be established by non-invasive 
imaging techniques, including ultrasonography, CT-scan and MRI. Once EPVT has been 
diagnosed, the cause of EPVT should be elucidated. Local risk factors are mainly infec-
tious and inflammatory diseases, but also abdominal trauma and surgery can cause 
EPVT. Systemic risk factors are acquired or inherited prothrombotic disorders. Over the 
last decade significant advances have been made in identifying prothrombotic predis-
positions in patients with thrombosis. By JAK2 mutation screening more evidence can 
be obtained for the presence of a latent or overt MPD as underlying cause of EPVT. The 
treatment goal of EPVT can be divided into two broad aims: (i) to reverse or to prevent 
recurrence or extension of thrombosis within the portal venous system and (ii) to treat 
the portal hypertension complications of chronic EPVT.
In chapter 2 we give a general overview of management of non- cirrhotic non- malignant 
EPVT patients and the concurrent portal hypertension complications. Esophagogastric 
variceal bleeding is the most important complication of chronic EPVT. In one fourth of 
the EPVT patients variceal bleeding is the presenting symptom. Endoscopic treatment is 
the first line intervention in patients with bleeding esophagogastric varices. In contrast 
to endoscopic treatment of variceal bleeding in patients with cirrhosis, little is known 
about the outcome of this treatment in adult patients with non- cirrhotic EPVT. In chap-
ter 3 we describe that patients with variceal bleeding had a rebleeding rate of 23% after 
the first year and this rate decreased over time with maintained endoscopic follow-up. 
The presence of fundal varices and extension of thrombosis into the splenic vein were 
predictors of variceal rebleeding. In contrast to patients with cirrhosis mortality was not 
determined by variceal (re)bleeding or endoscopic treatment complications.
A second phenomenon of portal hypertension is ascites. In contrast to patients with 
cirrhosis, where ascites is a poor prognostic feature, little is known of ascites in non- cir-
rhotic non- malignant patients with EPVT. In chapter 4 we described that in approxi-
mately a quarter of the patients ascites was present at the time EPVT was diagnosed. 
Most of these patients were patients with chronic EPVT. Seventy-five percent of these 
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patients were at risk for a second episode of ascites. In contrast to the literature, we did 
not find a correlation between the presence of ascites and gastrointestinal hemorrhage, 
renal insufficiency, sepsis or surgery. Also other causes that could clarify the presence 
of ascites, such as liver failure or low osmotic pressure, appeared unlikely, because all 
patients lacked any evidence of cirrhosis. It is known that the onset of ascites in patients 
with a history of thrombotic disease should heighten the clinical suspicion of mesente-
rial venous thrombosis. However, we found no correlation between the extension of the 
thrombus towards the superior mesenteric vein and the presence of ascites. We also 
found a remarkably high mortality rate in patients with ascites compared to patients 
without ascites at diagnosis.
The role of anticoagulation therapy in patients with EPVT is ambiguous. It is nowa-
days recommended to start anticoagulation therapy for patients with a recent EPVT to 
recanalize the portal vein and prevent extension of the thrombosis into the splanchnic 
veins. Considerably more controversy has surrounded the role of anticoagulants in 
patients with chronic EPVT. The reason to start anticoagulation therapy in these patients 
is to prevent new thrombotic events or extension of the thrombosis into the splanchnic 
veins in patients with a prothrombotic disorder. In chapter 5 we found that patients 
with a prothrombotic disorder were prone to develop extension of thrombosis into 
the splanchnic veins and in 20% of these patients a new thrombotic event occurred, 
which was significantly associated with decreased survival. Although anticoagulation 
decreased new thrombotic events, it significantly increased the risk of gastrointestinal 
bleeding. The severity of the bleeding was not affected by the use of anticoagulants. 
Gastrointestinal bleeding and anticoagulants use had both their effect on survival, 
but not statistically significant. By identifying predictive factors on the occurrence of a 
gastrointestinal bleeding as varices size, previous gastrointestinal bleeding, extended 
thrombosis and ascites together with the indication of anticoagulation therapy, a 
patient-based treatment strategy can be made.
Another treatment modality to recanalize the portal vein in patients with EPVT is 
thrombolysis. In the last decade we have performed transcatheter local thrombolytic 
therapy in patients with recent EPVT. In chapter 6 we assessed all patients, who un-
derwent this procedure in our center. A total of 12 patients were included of whom six 
patients had additional thrombosis of the hepatic veins (Budd- Chiari Syndrome) and 
two patients had cirrhosis. In three patients transcatheter local thrombolytic therapy 
was successful, in four patients the flow was restored in some vessels, but not all and 
in five patients no lysis was obtained in any of the occluded vessels. Fifty percent of the 
patients developed major procedure related bleeding with fatal outcome in two. This 
high complication rate makes this therapy unattractive and it should only be performed 
in patients with progressive thrombosis or clinical deterioration, where other treatment 
modalities as anticoagulants and TIPS placement have failed.
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In almost all patients with chronic EPVT biliary abnormalities can be found on radio-
logical imaging. In only a few patients this will lead to symptomatic manifestations. 
Data on this topic are scarce. In chapter 7 we assessed all patients with symptomatic 
biliary symptoms, either at the time of EPVT diagnosis or during follow up. During a 
median follow up of 5.5 years we found that 18 (15%) patients had signs of cholestasis 
related symptoms and 8 (7%) patients had symptomatic portal biliopathy. ERCP showed 
a stenosis in the proximal or mid CBD stenosis in all patients with a single diagnosed 
symptomatic portal biliopathy. Although repeated ERCP procedures per patient are 
necessary, ERCP as first line treatment seemed to be safe and successful in most patients 
with symptomatic portal biliopathy.
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sAmenVATTing en discussie
Dit proefschrift richt zich op patiënten met een extrahepatische vena porta trombose 
(EPVT) , waarbij er geen sprake is van levercirrose of maligniteit. Extrahepatische vena 
porta trombose wordt gedefinieerd als een obstructie van de extrahepatische vena 
porta met of zonder uitbreiding naar de intrahepatisch gelegen portale venen en omvat 
niet een geïsoleerde thrombose van de vena lienalis of vena mesenterica superior. De 
symptomen zijn afhankelijk van de duur van de trombose. De klassieke presentatie 
van een acute EPVT gaat gepaard met buikpijn. Daarbij kunnen ook koorts en ascites 
aanwezig zijn. De ascites is meestal gering en van voorbijgaande aard. De symptomen 
van een chronische EPVT zijn gerelateerd aan de door portale hypertensie ontstane 
complicaties , zoals gastro-intestinale bloedingen, miltvergroting en ascites. Bij de 
meeste patiënten bij wie EPVT vermoed wordt kan de diagnose gesteld worden door 
middel van niet invasieve beeldvorming, zoals echo, CT-scan en MRI. Zodra de diagnose 
EPVT vastgesteld is, is het zaak de oorzaak van de EPVT op te sporen. Locale factoren, 
die tot EPVT kunnen leiden, zijn vooral lokale infecties en inflammatoire darmziekten, 
maar ook een buiktrauma of een operatieve ingreep kunnen de oorzaak zijn van EPVT. 
Systemische ziekten, die tot EPVT leiden, zijn verworven of erfelijke protrombotische 
ziekten. In de laatste tien jaar zijn er aanzienlijke vorderingen gemaakt ten aanzien van 
het opsporen van genetische varianten, die leiden tot een verhoogd trombose risico bij 
patiënten met een doorgemaakte trombose. Door screening op een JAK2 mutatie kan 
een latente of reeds aanwezige myeloproliferatieve ziekte als onderliggende oorzaak 
van EPVT aangetoond worden.
De behandeling van een acute EPVT is er op gericht om de trombose in het portale 
systeem op te lossen en een recidief te voorkomen. Bij chronische EPVT is de behande-
ling er op gericht de complicaties van de portale hypertensie te bestrijden.
In hoofdstuk 2 wordt een overzicht gegeven van de behandeling van patiënten 
met een EPVT en de hiermee samenhangende complicaties van portale hypertensie. 
Gastro-intestinale bloedingen zijn de belangrijkste complicatie bij patiënten met een 
chronische EPVT.
In een kwart van de patiënten is een varix bloeding de eerste uiting van chronische 
EPVT. Endoscopische behandeling is dan de behandeling van keuze. In tegenstelling 
tot patiënten met levercirrose is er weinig bekend over het effect van endoscopische 
behandeling van varices bloedingen bij volwassen patiënten met EPVT zonder levercir-
rose. In hoofdstuk 3 beschrijven we dat 23% van de patiënten met een varix bloeding 
na één jaar een tweede bloeding heeft gehad, waarbij de kans op een nieuwe bloeding 
met de tijd afnam. Factoren, die gepaard gingen met een verhoogd risico op reci-
diefbloedingen waren de aanwezigheid van varices in de maag en uitbreiding van de 
trombose in de vena lienalis. In tegenstelling tot patiënten met levercirrose, bij wie een 
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varix bloeding gepaard gaat met een hoge mortaliteit, vonden we bij patiënten zonder 
levercirrose geen relatie tussen (recidief ) bloeding, complicaties van de endoscopische 
behandeling en het overlijden van de patiënt.
Een tweede kenmerk van portale hypertensie is ascites. In tegenstelling tot patiënten 
met levercirrose, waarbij ascites een slechte prognostische factor is, is er weinig bekend 
over ascites bij patiënten met EPVT. In hoofdstuk 4 beschrijven we dat in ongeveer een 
kwart van de patiënten ascites aanwezig was op het moment dat de diagnose EPVT 
gesteld werd. Het merendeel van deze patiënten had een chronische EPVT. Vijfenze-
ventig procent van deze patiënten ontwikkelde opnieuw ascites. In tegenstelling tot 
de literatuur vonden we geen correlatie tussen de aanwezigheid van ascites en gastro-
intestinale bloedingen, nierinsufficiëntie, sepsis of status na een operatie. Ook andere 
oorzaken die de ascites zouden kunnen verklaren, zoals leverfalen of lage osmotische 
druk, leken onwaarschijnlijk omdat er bij geen van de patiënten aanwijzingen waren 
voor levercirrose. Het is bekend dat bij patiënten met een verhoogde tromboseneiging 
en ascites er een aanzienlijke kans is dat er sprake is van een mesenteriaal trombose. 
Daarentegen vonden wij geen correlatie tussen de uitbreiding van de trombose naar 
de vena mesenterica superior en de aanwezigheid van ascites. Tevens vonden wij een 
opmerkelijk hoge sterfte bij patiënten met ascites vergeleken met patiënten zonder 
ascites ten tijde van het stellen van de diagnose.
De rol van antistolling bij patiënten met EPVT is niet eensluidend. In de huidige richt-
lijnen wordt aanbevolen antistolling te starten bij patiënten met een acute EPVT met als 
doel de vena porta te rekanaliseren en uitbreiding van de trombose naar de darmvenen 
te voorkomen. De rol van het gebruik van antistolling bij patiënten met een chronische 
EPVT is aanzienlijk meer omstreden en lijkt met name weggelegd voor patiënten met 
een protrombotische ziekte om te voorkomen dat een nieuwe trombose ontstaat of dat 
er uitbreiding van de trombose naar de darmvenen plaatsvindt. In hoofdstuk 5 laten 
we zien dat patiënten met een protrombotische ziekte een verhoogde kans hadden op 
uitbreiding van de trombose naar de darmvenen en dat 20% van deze patiënten een 
nieuwe trombose ontwikkelde, hetgeen significant geassocieerd was met een verkorte 
levensduur. Hoewel antistolling de kans op een nieuwe trombose verminderde was 
er een significant verhoogde kans op het krijgen van een gastro-intestinale bloeding. 
Het gebruik van antistolling had geen invloed op de ernst van de bloeding. Gastro-
intestinale bloedingen en het gebruik van antistolling hadden beiden invloed op de 
overleving maar waren niet statistisch significant. Door factoren, die gepaard gaan met 
een verhoogd risico op gastro-intestinale bloedingen, op te sporen, zoals de grootte 
van de varices, eerdere gastro-intestinale bloedingen, uitgebreide trombose en ascites, 
en deze af te zetten tegen de indicatie voor antistolling kan een geïndividualiseerde 
behandelstrategie opgesteld worden.
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Een andere behandelmethode bij patiënten met acute EPVT, om de vena porta te 
rekanaliseren is trombolyse. In de laatste tien jaar werd lokale trombolyse verricht bij 
patiënten met recente EPVT. In hoofdstuk 6 hebben we alle patiënten geanalyseerd 
die deze procedure in ons centrum hebben ondergaan. Twaalf patiënten werden in de 
analyse opgenomen waarvan zes patiënten een trombose van de venae hepaticae had-
den (Budd- Chiari Syndroom) en twee patiënten levercirrose. Bij drie patiënten was deze 
lokale behandeling met trombolyse succesvol, in vier patiënten werd de bloedstroom in 
enkele vaten hersteld maar niet in alle en in vijf patiënten werd geen effect gezien. Vijf-
tig procent van de patiënten kreeg een aan de procedure gerelateerde grote bloeding 
met bij twee patiënten een fatale afloop. Dit hoge complicatie risico maakt dat deze 
therapie slechts in uiterste omstandigheden te overwegen is als alle andere therapie 
modaliteiten geen effect gehad hebben en er sprake is van uitbreiding van de trombose 
of klinische verslechtering.
Bij bijna alle patiënten met chronische EPVT kunnen bij radiologisch onderzoek af-
wijkingen aan de galwegen gevonden worden. Bij slechts weinig patiënten geeft dit 
aanleiding tot symptomen. Data hierover zijn schaars. In hoofdstuk 7 hebben we alle 
patiënten geanalyseerd met symptomatische galweg klachten, hetzij ten tijde van de 
diagnose EPVT , hetzij tijdens de follow-up. We vonden dat gedurende een mediane 
follow-up van 5,5 jaar 18 (15%) patiënten cholestase gerelateerde symptomen hadden 
en 8 (7%) patiënten hadden symptomatische portale biliopathie. Bij patiënten met een 
symptomatische portale biliopathie zonder andere cholestase gerelateerde factoren, 
werd bij ERCP een stenose gevonden in het proximale of middelste deel van de ductus 
choledochus communis. Hoewel er meerdere ERCP’s per patiënt nodig zijn, lijkt deze 
eerste keus behandeling effectief en veilig.
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